RESEARCH ARTICLE

Genes Related to Sex Steroids, Neural Growth, and Social–Emotional Behavior are Associated with Autistic Traits, Empathy, and Asperger Syndrome

B. Chakrabarti, F. Dudbridge, L. Kent, S. Wheelwright, G. Hill-Cawthorne, C. Allison, S. Banerjee-Basu, and S. Baron-Cohen

Genetic studies of autism spectrum conditions (ASC) have mostly focused on the "low functioning" severe clinical subgroup, treating it as a rare disorder. However, ASC is now thought to be relatively common (∼1%), and representing one end of a quasi-normal distribution of autistic traits in the general population. Here we report a study of common genetic variation in candidate genes associated with autistic traits and Asperger syndrome (AS). We tested single nucleotide polymorphisms in 68 candidate genes in three functional groups (sex steroid synthesis/transport, neural connectivity, and social–emotional responsivity) in two experiments. These were (a) an association study of relevant behavioral traits (the Empathy Quotient (EQ), the Autism Spectrum Quotient (AQ)) in a population sample ($n = 349$); and (b) a case–control association study on a sample of people with AS, a "high-functioning" subgroup of ASC ($n = 174$). 27 genes showed a nominally significant association with autistic traits and/or ASC diagnosis. Of these, 19 genes showed nominally significant association with AQ/EQ. In the sex steroid group, this included *ESR2* and *CYP11B1*. In the neural connectivity group, this included *HOXA1*, *NTRK1*, and *NLGN4X*. In the socio-responsivity behavior group, this included *MAOB*, *AVPR1B*, and *WFS1*. Fourteen genes showed nominally significant association with AS. In the sex steroid group, this included *CYP17A1* and *CYP19A1*. In the socio-emotional behavior group, this included *OXT*. Six genes were nominally associated in both experiments, providing a partial replication. Eleven genes survived family wise error rate (FWER) correction using permutations across both experiments, which is greater than would be expected by chance. *CYP11B1* and *NTRK1* emerged as significantly associated genes in both experiments, after FWER correction ($P<0.05$). This is the first candidate-gene association study of AS and of autistic traits. The most promising candidate genes require independent replication and fine mapping.

Keywords: genetics; Asperger syndrome; autism; empathy; autistic traits; visual search; emotion recognition; SNP; broader autism phenotype

Introduction

Autism spectrum conditions (ASC) entail a disability in social and communication development, alongside unusually narrow interests ("obsessions") and repetitive behavior [APA, 1994; ICD-10, 1994]. ASC have a genetic basis, indicated by concordance rates from MZ and DZ twins [Bailey et al., 1995], and with heritability estimates of over 90% [Bailey et al., 1995; LaBuda, Gottesman, & Pauls, 1993]. Multiple common susceptibility alleles are implicated, along with environmental and epigenetic factors. Mixed evidence from genome-wide linkage studies of samples that do not differentiate between classic (low-functioning) autism and autism spectrum disorder have implicated nearly all chromosomes [Abrahams & Geschwind, 2008]. This could be due to genetic heterogeneity, or potential confounds from comorbid conditions (e.g. epilepsy, language delay, below average IQ, or hyperactivity).

While most neuroimaging and behavioral studies of ASC focus on the higher-functioning end of the autism spectrum (high-functioning autism and/or Asperger syndrome (AS)), the large-scale genetic studies have primarily investigated the lower-functioning end, focusing on classic autism. In this study, we address this important gap in literature, by reporting two genetic association studies. The first is of AS, and the second is of autistic traits in the general population. AS is marked by social and behavioral impairments, but is not associated with language delay during development. We chose 68 candidate genes for these two experiments, derived from

three functional categories: (A) sex hormone-related genes; (B) genes involved in neural development and connectivity; and (C) genes involved in social and emotional responsivity (Table I). We searched for common genetic variants (single nucleotide polymorphisms (SNPs)) on the assumption that autistic traits are continuously distributed in the general population [Constantino & Todd, 2005; Sung et al., 2005]. Each of the three functional categories derives from a clear neurocognitive theory of ASC. The fetal androgen theory [Baron-Cohen, Lutchmaya, & Knickmeyer, 2004] suggests that genes involved in sex steroid synthesis and transport might be related to ASC. The neural connectivity theory [Belmonte et al., 2004], based on evidence from rat and human brains suggests that the key abnormality in autism might be related to neural growth and connectivity.

Therefore, genes involved in neural growth, synaptogenesis, and synapse stabilization were included in our set of candidates. Finally, the social–emotional responsivity theory [Chakrabarti, Kent, Suckling, Bullmore, & Baron-Cohen, 2006; Dawson et al., 2002] suggests that the aberrant social behavior patterns noticed in ASC might be related, in part, to genes that are known to modulate social behavior in animals. The rationale of choice for all genes, together with relevant gene function, is described in detail in the online Supplementary material (S1). Some of these genes have been associated with autism in previous genetic studies, and these are indicated in bold in Table I. These 68 candidate genes were tested in two experiments.

In Experiment 1, we measured autistic traits in a population-based sample of volunteers without any psychiatric diagnoses, to test whether any of these genes

Table I. List of All Genes Included in the Association Study, Along with Brief Functional Roles Where Known

Neural development and connectivity	
*NGF, BDNF, NTF*3, *NTF*5, *NGFR, NTRK*1, *NTRK*2, *NTRK*3, *TAC*1, *IGF*1, *IGF*2	Neuronal survival, differentiation and growth.
*RAPGEF*4	Growth and differentiation of neurons. Mutations associated with classic autism.
VGF	Upregulated directly by NGF and expressed in neuroendocrine cells.
VEGF	Promotes cell growth and migration, especially during angiogenesis and vasculogenesis, often observed during hypoxia. Modulated directly by PTEN.
*ARNT*2	Neural response to hypoxia.
*NLGN*1, ***NLGN4X***, *AGRIN*	Synapse formation and maintenance in CNS neurons. *NLGN4X* mutations have been linked to autism.
NRCAM	Neuronal adhesion and directional signalling during axonal cone growth.
EN-2 (AUTS1)	Neuronal migration and cerebellar development. *EN-2* has been previously linked to ASCs in several studies.
HOXA1	Hindbrain patterning. Mixed evidence suggests a link with ASCs.
Social and emotional responsivity	
OXT, ***OXTR, AVPR1A,*** *AVPR*1B	Linked to social attachment behavior in humans and other mammals. *AVPR1A* and *OXTR* have previously been associated with ASCs.
*CNR*1, *OPRM*1, *TRPV*1	Mediate endogenous reward circuits, in tandem with dopaminergic pathways. Implicated in underlying rewarding features of social interactions.
MAOB	Synaptic breakdown of dopamine and serotonin. Suggested links with social cognition.
*WFS*1	Mutations linked to affective disorders. Overexpressed in amygdala during fear response, though exact functional role is not known.
GABRB3, GABRG3, *GABRA*6, ***ABAT***	Mediate inhibitory (GABA-ergic) neurotransmission as well as play a role in early cortical development. *GABRA*6 is expressed strongly in the cerebellum; *GABRB*3, *GABRG*3, *ABAT* have all been associated with ASCs.
*VIPR*1	Suggested involvement in neural pathway underlying pheromone processing. Mutations associated with social behavioral abnormalities in mice. Its endogenous ligand (VIP) shows an overexpression in neonatal children with autism.
Sex hormone biosynthesis, metabolism and transport	
*DHCR*7	Metabolism of cholesterol: precursor for sex hormones (mutations associated with near-universal presence of ASC).
*CYP1A*1, *CYP1B*1, *CYP3A, CYP7A*1, *CYP11A, CYP11B*1, *CYP17A*1, *CYP19A*1, *CYP21A*2, *POR*	Synthesis of sex hormones such as progesterone, estrogen, cortisol, aldosterone and testosterone. *CYP21A*2 and *POR* mutations associated with CAH.
*HSD11B*1, *HSD17B*2, *HSD17B*3, *HSD17B*4	Local regulation of sex steroids.
*STS, SULT2A*1, *SRD5A*1, *SRD5A*2	Steroid hormone metabolism.
*SHBG, SCP*2, *TSPO, SLC25A*12, *SLC25A*13	Intracellular transport of sex steroids as well as their important precursors and/or metabolites. Mixed evidence suggests an association of *SLC25A*12 with classic autism.
AR	Intracellular receptor for testosterone.
*ESR*1, *ESR*2	Receptors for estrogen.
CGA, CGRPR, LHB, LHRHR, LHCGR, FSHB	Regulation of reproductive functions.

Genes marked in bold indicate those previously linked to ASC through genetic linkage/association studies. For list of SNPs chosen from each gene, see Table II. Yellow [dark grey] = Neural growth genes; Light grey = Social responsivity genes; Pink [medium grey] = Sex steroid genes. [Color table can be viewed online at www.interscience.wiley.com]

were associated with autistic traits. Our primary measure of autistic traits is the Autism Spectrum Quotient (AQ) [Baron-Cohen, Wheelwright, Skinner, Martin, & Clubley, 2001b], a 50-point self-report scale with a quasi-normal distribution in the general population. The AQ has good reliability and validity, with 80% of people with AS scoring above 32/50 compared to 1.5% of controls, and males scoring higher than females [Baron-Cohen et al., 2001b]. AQ results have been replicated cross-culturally, and it is independent of IQ, age, education, major personality traits [Wakabayashi, Baron-Cohen, & Wheelwright, 2006], and scores above 32 is an excellent predictor of AS diagnosis [Woodbury-Smith, Robinson, Wheelwright, & Baron-Cohen, 2005]. AQ shows heritability of ~57% in twins [Hoekstra, Bartels, Verweij, & Boomsma, 2007], and in parents of children with ASC [Bishop et al., 2004].

Our second measure of autistic traits focused on individual differences in empathy. Empathy is a core deficit in ASC [Baron-Cohen, 1995]. The Empathy Quotient (EQ) [Baron-Cohen & Wheelwright, 2004] is a valid and reliable measure of empathy [Lawrence, Shaw, Baker, Baron-Cohen, & David, 2004], females scoring higher than males, and 81% of people with AS scoring less than 30/80 compared to 12% of controls [Baron-Cohen & Wheelwright, 2004]. Twin studies have established a genetic basis for empathy in humans [Zahn-Waxler, Robinson, & Emde, 1992]. Specific genes have also been implicated in empathy-related behavior in humans and other animals [Champagne et al., 2006]. The AQ and EQ allow a wider net to be cast in capturing genes underlying autistic traits.

In addition to the questionnaire measures, we used two performance measures related to autistic traits: the "Reading the Mind in the Eyes" (Eyes) Test of empathy [Baron-Cohen, Joliffe, Mortimore, & Robertson, 1997; Baron-Cohen, Wheelwright, Hill, Raste, & Plumb, 2001a] on which people with ASC score below average; and the Embedded Figures Test (EFT) of attention to detail [Jolliffe & Baron-Cohen, 1997] on which people with ASC score above average. Both are normally distributed in the population and are candidate endophenotypes, since parents and siblings of children with ASC show mild deficits on the Eyes test and above average performance on the EFT [Baron-Cohen & Hammer, 1997; Dorris, Espie, Knott, & Salt, 2004; Losh & Piven, 2007]. The EFT and Eyes tests tap highly specific components within autistic traits (emotion–recognition, and attention to detail), strengthening measures of these within the AQ and EQ.

In Experiment 2, we tested the same 68 genes for association in a sample of people with clinically diagnosed AS, the "high-functioning" subgroup on the autistic spectrum, in a case–control design. Almost all previous genetic studies have been conducted on samples that included both people with classic (Kanner's) autism as well as those with a diagnosis of Autism Spectrum Disorder, an approach that dates back to when ASC were regarded as rare. Today ASC is thought of as relatively common (~1%) [Baird et al., 2006; Baron-Cohen et al., 2009]. If autism is the extreme of normally distributed autistic traits, then AS is the more logical subgroup to investigate, since restricting the case sample to AS removes a suite of comorbid features. This increases the power to detect genes underlying autistic traits, independent of genes underlying learning difficulties or language delay. Family pedigrees of AS suggest heritability [Gillberg, 1991] and one full genome scan of AS has been conducted [Ylisaukko-oja et al., 2004], revealing strong linkage peaks at 1q21–22, 3p14–24, and 13q31–33.

We predicted that genes from each of the three functional categories would show significant association with caseness (certain alleles being more common in the AS group relative to population controls) and/or with individual differences on the phenotypic measures (AQ, EQ, the Eyes, and the EFT), in the population sample.

Materials and Methods
Samples

Individuals ($n = 349$; 143 males and 206 females, mean age = 22.5 years, SD = 2.6 years) free of any neurological/psychiatric diagnoses were recruited by advertisement from a student population. A student population inevitably means IQ distribution is not representative, but this is unlikely to introduce confounds since scores on the AQ [Billington, Baron-Cohen, & Wheelwright, 2007], EQ [Lawrence et al., 2004], Eyes Test [Baron-Cohen et al., 2001a] and EFT (unpublished data) are all independent of IQ. Participants were included only if they reported Caucasian ancestry for three generations. They filled in the AQ and EQ online, and the results were comparable to those reported previously by our and other groups. The mean EQ score was 44.1 (range: 9–75, mean score for males: 36.1, mean score for females: 49.6), and the mean AQ score was 16.43 (range: 3–36, mean score for males: 18.01, mean score for females: 15.33). AQ and EQ scores showed a modest negative correlation (Spearman's rho = -0.55, $P \leq 0.01$). A subset of this sample ($n = 96$) completed an online version of the Eyes Task and the EFT.

In addition, $n = 174$ cases (140 males and 34 females, mean age = 23.2 years, SD = 14.6 years) with a formal diagnosis of AS (based on DSM-IV or ICD-10) from independent clinicians were recruited through our online database. Cases were excluded if they had comorbid major psychiatric conditions (psychosis, schizophrenia, or bipolar disorder), or if they reported incompatible diagnostic features (such as a history of language delay or learning difficulties), or if they were self-diagnosed, or if

the clinician making the diagnosis was not affiliated to a recognized specialist psychiatric clinic. DSM-IV and ICD-10 criteria were used rather than ADI-R/ADOS, as the latter were designed to diagnose classic autism and their accuracy in diagnosing AS has not been confirmed. To our knowledge, this is the largest reported sample for a genetic association study of AS. As a check on diagnosis, approximately half of the cases of AS (91 of 174) also filled in the AQ. One would expect 80% of cases with AS to score equal to or more than 32 [Baron-Cohen et al., 2001b]. Out of the 91 cases, 73 (80.2%) scored at this level, confirming this sample was comparable to other published samples. As a check on IQ of the AS sample, approximately 10% of the AS group ($n = 19$) were randomly selected and administered the WASI full scale IQ test. This revealed a mean full-scale IQ score of 119.5 (SD = 21.1), which is comparable to that of a larger pool of typical student participants that these volunteers were drawn from. Ethnicity information was available for 106/174 (60.9%) of the cases, all of who were Caucasian for at least three generations. To control for possible confounds from missing ethnicity data among cases, χ^2 analyses were performed for each SNP from Table II, comparing cases with and without ethnicity information. This revealed no differences in allele frequencies between these two groups for all but two SNPs, consistent with genetic homogeneity of the cases.

SNP Selection

SNPs (216) with a minor allele frequency (MAF) ≥ 0.2 in the Caucasian population were chosen, to ensure adequate power given our sample size, which was fixed by external constraints prior to the study. This approach of selecting multiple common SNPs per gene has the advantage of checking for informative associations both directly and indirectly [Collins, Guyer, & Chakravarti, 1997]. SNPs (from dbSNP build 123) were chosen randomly from across the whole gene, including UTRs and introns. The number of SNPs per gene varied with the gene size and number of commercially available ABI assays, and is detailed in Table II. The median SNP density across all genes was one SNP per 14.1 kb; 125 of these SNPs have been genotyped in one or more populations in the HapMap database (Release 23a). We used TAGGER to estimate the coverage, which revealed that 40 SNPs were in strong LD with SNPs genotyped in the HapMap database. These SNPs covered 7.3% of HapMap variation at $r^2 > 0.8$ and 13.26% at $r^2 > 0.5$, for SNPs with MAF > 0.001. The remaining 176 of our SNPs did not exhibit a strong LD with the genotyped SNPs in the HapMap database, and hence the true coverage is considerably higher than our estimate. It should be noted that in absence of complete polymorphism data

on the same sample, it is not possible to estimate the actual gene coverage.

All volunteers contributed mouth swabs for DNA extraction. These were anonymized and DNA was genotyped for the SNPs (see Table II) using standard PCR-based assays (TaqMan® SNP genotyping assays, Applied Biosystems Inc., CA). The genotyping call rate was 93.35% across all samples. Concordance for duplicate samples was 99.8%. No SNP showed a significant deviation from Hardy–Weinberg Equilibrium at $P < 0.001$. The following experiments were performed:

1. *An association study for AQ and EQ* was conducted on the population sample ($n = 349$) using nonparametric (Kruskal–Wallis) analysis of variance for each SNP, since neither the AQ nor the EQ were normally distributed in our sample (Anderson–Darling statistic = 3.26). χ^2 statistics and asymptotic P-values (two-tailed) were generated from this test. A sex-specific analysis was conducted for all X-linked genes. A similar analysis for the EFT and Eyes tasks was undertaken in a subset of this sample ($n = 96$), using univariate ANOVA for each SNP, since neither EFT and Eyes task scores deviated significantly from normality.

2. *A case–control association study* was conducted on all cases of AS ($n = 174$) and a subset of the population sample ($n = 155$). The controls were selected to be sex-matched with the cases, while having an AQ score < 25. An AQ < 25 cut-off was employed to exclude a small number of individuals who scored high on AQ even though they did not have a formal diagnosis. For each SNP, a Cochrane–Armitage χ^2 statistic (1 d.f.) was calculated to test the null hypothesis that the different alleles have the same distribution in cases and controls. Asymptotic P-values (two-tailed) were calculated. In addition, a Pearson's χ^2 (2 d.f., "codominant" test) was calculated for each SNP (see Supplementary Table S2).

To control for multiple testing of SNPs within genes as well as for multiple phenotypes, permutation testing was conducted using UNPHASED [Dudbridge, 2008] for Experiment 1, and using PLINK [Purcell et al., 2007] for Experiment 2. Since each candidate gene was individually selected on the basis of *a priori* hypothesis, independent of other genes, permutation tests were performed separately for each gene. In each permutation, the phenotypes were randomly reassigned among participants, keeping the genotypes fixed to preserve

Table II. The List of All SNPs Genotyped, Grouped by Gene

Gene variations	Experiment 1						Experiment 2		
	EQ (χ^2 statistic)	EQ (P-value)	AQ (χ^2 statistic)	AQ (P-value)	Additional data	Permutation-corrected P-value	C-A trend test χ^2 statistic	C-A trend test P-value	Permutation-corrected P-value
AGRN									
rs2275813	2.168	0.338	4.431	0.109	Eyes		0.071	0.790	
rs8014	0.289	0.865	2.194	0.334			1.77	0.180	
NRCAM									
rs445372	2.299	0.317	2.024	0.363			0.31	0.580	
rs1269621	0.721	0.697	0.28	0.869			1.45	0.230	
rs1269655	0.638	0.727	0.792	0.673			1.096	0.290	
NTRK1						0.034			0.018
rs6334	0.007	0.935	1.591	0.207			2.67	0.100	
rs6337	1.367	0.505	2.237	0.327			7.54*	0.010	
rs1007211	0.085	0.958	1.988	0.370			1.01	0.320	
rs6339	9.184*	0.010	3.684	0.158			0.2	0.650	
NTRK2									
rs7027979	0.901	0.637	1.924	0.382			0.38	0.540	
rs11140776	0.277	0.871	0.354	0.838			0.47	0.490	
rs10780691	2.568	0.277	2.073	0.355			0.002	0.960	
rs1490404	1.93	0.381	0.652	0.722			0.24	0.620	
rs1778934	0.63	0.730	3.201	0.202			0.65	0.420	
rs2489162	0.135	0.935	2.853	0.240			0.03	0.860	
rs1619120	1.809	0.405	2.019	0.364	Eyes		0.06	0.810	
rs993315	0.528	0.768	0.881	0.644			0.77	0.370	
rs1624327	1.532	0.465	1.787	0.409			0.004	0.950	
rs1443444	0.568	0.753	1.602	0.449			0.02	0.890	
NTRK3						0.132			0.249
rs1948066	3.74	0.154	2.471	0.291			0.44	0.510	
rs7170215	3.976	0.137	1.901	0.387	Eyes		0.41	0.840	
rs920069	7.024*	0.030	11.984*	0.002			2.03	0.150	
rs1824554	0.239	0.625	5.246*	0.022			0.15	0.690	
rs7170976	0.115	0.944	0.053	0.974			0.09	0.750	
rs922231	2.424	0.298	1.032	0.597			3.12	0.080	
rs8030107	0.727	0.695	0.378	0.828			2.1	0.150	
rs2279409	1.256	0.534	6.324*	0.042			0.004	0.940	
rs11073762	0.594	0.743	5.747	0.057			0.011	0.910	
rs3784410	1.964	0.375	3.064	0.216			0.59	0.440	
rs7176429	6.474*	0.039	5.468	0.065			0.44	0.510	
rs1369430	3.144	0.208	3.633	0.163			4.66*	0.030	
rs3784441	3.189	0.203	2.637	0.268			1.36	0.240	
rs1369423	3.054	0.217	2.526	0.283			1.9	0.170	
NLGN1									
rs993298	0.482	0.786	0.056	0.972			0.6	0.440	
NLGN4X						0.167/0.024			
rs5916338	1.396/1.267	0.237/0.531	0.324/0.468	0.569/0.791			0.73/0.80	0.39/0.37	

Table II. Continued

	Experiment 1						Experiment 2		
Gene variations	EQ (χ^2 statistic)	EQ (*P*-value)	AQ (χ^2 statistic)	AQ (*P*-value)	Additional data	Permutation-corrected *P*-value	C-A trend test χ^2 statistic	C-A trend test *P*-value	Permutation-corrected *P*-value
rs12836764	4.919*/5.070	*0.027*/0.079	1.835/8.555*	0.176/*0.014*			0.00006/0.48	0.99/0.49	
NGFB									
rs6330	0.11	0.947	0.753	0.686			0.01	0.920	
rs910330	1.04	0.595	5.441	0.066			0.53	0.470	
NGFR									
rs575791	0.537	0.765	0.844	0.656			3.62	0.057	
EN2						0.134			
rs2361689	0.514	0.773	1.78	0.411	Eyes		0.07	0.790	
rs1861972	8.478*	*0.014*	2.964	0.227	Eyes, EFT		0.033	0.850	
rs3735653	1.107	0.575	3.121	0.210			0.12	0.730	
HOXA1						*0.029*			
rs10951154	5.71	0.058	7.563*	*0.023*			0.25	0.620	
NTF3									0.053
rs6332	2.618	0.270	2.054	0.358			0.13	0.720	
rs7958038	0.17	0.918	1.986	0.370			1.69	0.190	
rs7132127	0.139	0.933	1.939	0.379			6.5*	*0.010*	
rs4930767	4.968	0.083	0.22	0.896			1.35	0.250	
NTF5									
rs1611775	0.19	0.909	2.119	0.347			0.29	0.590	
VGF									
rs2074686	0.847	0.655	0.235	0.889			1.34	0.250	
rs10953325	1.055	0.590	1.313	0.519			0.05	0.820	
rs1859528	0.122	0.941	1.154	0.562			0.85	0.350	
VEGF									
rs833068	4.155	0.130	4.082	0.212			2.41	0.120	
rs3025020	3.815	0.157	2.774	0.099	Eyes		0.25	0.620	
RAPGEF4 (cAMP-GEFII)									
rs6754857	0.194	0.908	0.653	0.721			0.49	0.485	
rs17746510	0.116	0.944	0.562	0.755			0.21	0.650	
rs2676501	0.429	0.807	0.05	0.975			1.38	0.240	
TAC1									
rs1229434	2.269	0.322	0.153	0.926			3.8	0.052	
rs2072100	1.279	0.527	0.006	0.997			1.39	0.237	
IGF1									0.115
rs11111272	1.466	0.480	2.309	0.315			0.049	0.820	
rs972936	0.902	0.342	3.33	0.068			1.51	0.227	
rs2946834	1.072	0.585	0.664	0.718			4.31*	*0.037*	
rs10735380	1.749	0.417	2.605	0.272			0.228	0.630	
IGF2									
rs2239681	0.158	0.924	1.789	0.409			0.029	0.864	
rs11042751	0.683	0.711	1.952	0.377			1.054	0.305	
rs734351	0.617	0.735	3.019	0.221			0.081	0.776	

Chakrabarti et al./Genes for autistic traits and/or ASC

BDNF								
rs6265	1.117	0.572	0.837	0.658		0.989	0.320	
ARNT2					0.184			*0.018*
rs4778599	3.038	0.219	11.127*	*0.004*		2.369	0.120	
rs4778795	2.485	0.289	2.458	0.293		3.076	0.079	
rs11856273	0.297	0.862	1.855	0.395		0.003	0.953	
rs3901896	4.749	0.093	3.246	0.197		8.45*	*0.003*	
rs7403073	2.441	0.295	0.305	0.858		0.53	0.460	
OXT								*0.016*
rs2740204	1.206	0.547	1.843	0.398		1.93	0.160	
rs2770378	1.924	0.382	2.749	0.253		6.76*	*0.009*	
OXTR					0.471			
rs237880	1.822	0.402	7.092*	*0.029*		1.81	0.180	
rs237885	0.516	0.773	2.539	0.281		1.069	0.301	
rs237898	5.074	0.079	1.134	0.567		0.023	0.870	
rs2228485	0.076	0.963	3.642	0.162		0.37	0.540	
rs237902	3.063	0.216	4.218	0.121		0.69	0.400	
AVPR 1A								
rs1042615	0.116	0.944	3.704	0.157		2.177	0.140	
AVPR1B					0.058			
rs28405931	6.082*	*0.048*	4.251	0.119		1.237	0.260	
OPRM1								
rs648893	0.258	0.879	1.491	0.475		1.315	0.250	
rs495491	5.556	0.062	4.466	0.107		0.017	0.890	
rs1381376	5.015	0.081	1.133	0.568		2.304	0.130	
rs1799971	2.696	0.260	0.234	0.890		0.1459	0.702	
CNR1					0.156			
rs6454674	4.616	0.099	5.331	0.070		0.0004	0.980	
rs806380	0.247	0.884	1.041	0.594		2.01	0.150	
rs806377	4.534	0.104	6.446*	*0.040*		0.87	0.350	
rs1049353	9.422*	*0.009*	1.682	0.431		0.48	0.490	
TRPV1								
rs224534	0.441	0.802	1.143	0.565		0.31	0.570	
rs222747	0.038	0.981	2.639	0.267		0.16	0.700	
rs8065080	0.246	0.884	1.534	0.464		0.0004	0.980	
rs224547	0.046	0.978	0.054	0.973		0.023	0.880	
GABRB3					0.005			
rs2873027	11.564*	*0.003*	3.864	0.145		2.243	0.134	
rs11161335	2.618	0.270	1.302	0.522		0.002	0.950	
GABRG3								
rs28431127	4.971	0.083	2.331	0.312		0.331	0.570	

Table II. Continued

Gene variations	Experiment 1						Experiment 2		
	EQ (χ^2 statistic)	EQ (*P*-value)	AQ (χ^2 statistic)	AQ (*P*-value)	Additional data	Permutation-corrected *P*-value	C-A trend test χ^2 statistic	C-A trend test *P*-value	Permutation-corrected *P*-value
rs4887536	0.372	0.830	2.237	0.327			0.49	0.480	
GABRA6						0.212			
rs13172914	1.7	0.427	1.763	0.414			0.11	0.730	
rs13183266	11.039*	*0.004*	3.532	0.171			0.39	0.530	
rs10037092	5.104	0.078	2.031	0.362	Eyes		0.56	0.460	
ABAT									
rs2302607	2.631	0.268	2.709	0.258	Eyes		0.2	0.655	
rs1731017	0.947	0.623	0.04	0.980			0.066	0.790	
rs1641010	0.692	0.707	0.522	0.770			0.793	0.373	
rs2270287	5.921	0.052	5.715	0.057			0.046	0.828	
rs1641003	0.768	0.681	3.721	0.156			3.384	0.068	
MAOB						0.551/*0.003*			
rs2283729	2.577/5.067	0.108/0.079	0.67/7.553*	0.413/*0.023*			0.00823/0.72	0.9277/0.397	
rs1799836	0.404/1.446	0.525/0.485	1.435/2.682	0.213/0.262			0.5759/0.20	0.4479/0.65	
VIPR						0.105			
rs417387	3.933	0.140	7.880*	*0.019*			1.47	0.224	
rs437876	2.006	0.157	0.321	0.571			0.25	0.620	
rs342511	3.582	0.167	1.858	0.395	EFT		1.67	0.196	
WFS1						*0.015*			
rs734312	9.905*	*0.007*	6.345*	0.042			0.006	0.930	
rs4234730	11.587*	*0.003*	7.143*	*0.028*			0.119	0.730	
rs1046322	0.314	0.855	0.253	0.881			0.69	0.400	
CGRPR									
rs35034167	0.35	0.839	0.427	0.808			1.66	0.190	
rs1983372	1.517	0.468	3.209	0.201	Eyes		1.84	0.174	
CGA									
rs981086	0.539	0.764	5.265	0.072			0.2818	0.595	
rs9444470	1.123	0.570	4.572	0.102			0.337	0.561	
rs9342103	1.591	0.451	0.332	0.847			2.413	0.120	
ESR1						0.777			0.296
rs4583998	0.959	0.619	0.442	0.802			1.696	0.192	
rs1884051	1.209	0.546	0.315	0.854			0.542	0.461	
rs827421	0.972	0.615	4.517	0.105			0.88	0.348	
rs2228480	0.364	0.834	0.203	0.904			0.2014	0.653	
rs11155819	2.987	0.225	7.178*	*0.028*			3.773*	0.052	
rs7774230	0.575	0.750	1.409	0.494			3.978*	*0.046*	
rs712221	1.405	0.495	1.354	0.508			2.75	0.090	
rs6905370	1.07	0.586	1.686	0.430			0.21	0.640	
rs1801132	0.733	0.693	0.709	0.702			1.83	0.176	
rs2077647	0.195	0.907	1.206	0.547			0.204	0.650	
ESR2						*0.006*			0.094
rs1271572	4.819	0.090	17.3*	*0.000*			3.04	0.080	

SNP							
rs1256030	5.141	0.076	14.527*	*0.001*		1.676	0.195
rs1152579	1.095	0.314	0.59	0.442		3.332	0.067
rs1152582	4.665	0.097	12.772*	*0.002*		4.236*	*0.039*
rs915057	4.799	0.091	14.3*	*0.001*		3.079	0.079
rs1256049	3.622	0.164	12.021*	*0.002*		0.829	0.362
AR1							
rs1204039	0.616/0.283	0.433/0.868	0.522/5.206	0.47/0.074	EFT(males)	0.09/2.221	0.759/0.1362
rs5918760	1.048/0.197	0.306/0.906	0.184/5.331	0.668/0.07	EFT(males)	0.013/1.68	0.906/0.942
rs6152	0.968/0.563	0.325/0.755	0.201/1.593	0.654/0.451	EFT(males)	0.01/1.31	0.928/0.352
LHB							
rs753307	4.699	0.095	1.818	0.403		1.593	0.206
LHCGR							0.138
rs4555391	5.659	0.059	3.213	0.201		4.51*	*0.030*
rs7584253	2.977	0.226	0.465	0.793		0.4249	0.515
rs6545061	2.804	0.246	1.41	0.494		0.382	0.536
rs2293275	0.294	0.863	0.388	0.824		0.033	0.850
GNRHR							
rs2062302	0.561	0.756	4.294	0.117		1.15	0.284
rs974483	2.729	0.255	1.126	0.569		0.252	0.615
FSHB							
rs532667	1.332	0.514	1.261	0.532		2.119	0.146
SULT2A1							
rs2547241	0.158	0.924	3.888	0.143		0.1072	0.743
rs182420	1.526	0.466	1.71	0.425		0.027	0.868
DHCR7							
rs4944957	0.639	0.726	2.31	0.315		0.8783	0.349
rs12419334	0.573	0.751	1.22	0.543		0.7621	0.383
rs736894	1.328	0.515	1.644	0.440		0.889	0.345
STS							
rs2024159	1.809/1.282	0.179/0.527	2.666/2.67	0.102/0.263		0.51/1.234	0.82/0.2667
rs7058445	1.45/1.757	0.228/0.415	2.175/3.521	0.14/0.172		0.06/0.7508	0.806/0.3862
HSD11B1							0.054
rs4844880	1.365	0.505	0.469	0.791		2.203	0.138
rs2884090	0.711	0.701	1.088	0.580		5.895*	*0.015*
rs11576775	4.072	0.131	4.147	0.125		0.6053	0.437
HSD17B2						0.390	
rs2873459	9.137*	*0.010*	4.666	0.097	Eyes	0.12	0.729
rs4398102	6.807*	*0.033*	3.367	0.186	Eyes	1.858	0.172
rs4445895	2.25	0.325	1.64	0.440		0.285	0.593
rs4497679	6.129*	*0.047*	2.978	0.226	Eyes	0.094	0.758
rs4889456	0.78	0.677	1.037	0.595		1.219	0.262

Table II. Continued

Gene variations	Experiment 1						Experiment 2		
	EQ (χ^2 statistic)	EQ (P-value)	AQ (χ^2 statistic)	AQ (P-value)	Additional data	Permutation-corrected P-value	C-A trend test χ^2 statistic	C-A trend test P-value	Permutation-corrected P-value
rs6564964	0.529	0.768	0.676	0.713			0.7722	0.379	
rs8044837	2.258	0.323	0.852	0.653			1.61	0.194	
HSD17B3									
rs1807197	0.914	0.633	0.488	0.784	EFT		0.009	0.924	
rs1927883	1.233	0.540	1.327	0.515	EFT		0.006	0.934	
rs2026001	0.93	0.628	1.796	0.407			1.531	0.215	
rs2476920	3.026	0.220	0.751	0.687	EFT		0.419	0.517	
rs2476923	0.866	0.876	2.055	0.358			0.4567	0.499	
rs371119	4.057	0.132	0.975	0.614	EFT		0.524	0.469	
rs913580	1.079	0.583	0.47	0.791	EFT		0.076	0.782	
HSD17B4						0.692			
rs25640	0.593	0.744	5.237	0.073			0.063	0.801	
rs257973	0.212	0.899	5.704	0.058			0.201	0.653	
rs32651	0.939	0.625	1.904	0.386			0.2877	0.592	
rs3850201	0.557	0.757	0.42	0.811			0.6343	0.426	
rs426899	1.021	0.600	1.712	0.425			0.733	0.392	
rs7737181	0.154	0.926	6.346*	0.042	Eyes		0.1114	0.739	
CYP1A1									
rs1456432	0.118	0.943	1.997	0.368			0.081	0.776	
rs2606345	2.38	0.304	1.63	0.443			0.199	0.655	
rs4646421	0.375	0.829	0.411	0.814			2.45	0.117	
CYP1B1									
rs162556	0.078	0.962	0.017	0.992	Eyes		2.236	0.134	
rs163086	0.806	0.668	3.304	0.192			2.4	0.121	
CYP3A									
rs2242480	1.616	0.446	0.595	0.743			0.027	0.869	
CYP7A1									
rs11786580	2.188	0.335	0.198	0.906			0.657	0.417	
rs10957056	2.746	0.253	0.015	0.993			0.236	0.627	
rs1023649	0.865	0.649	0.476	0.788	Eyes		1.44	0.230	
CYP11A									
rs2279357	2.103	0.349	0.39	0.823			1.22	0.270	
CYP11B1						0.033			0.010
rs4534	1.104	0.576	1.21	0.546			5.68*	0.017	
rs4541	1.046	0.593	1.604	0.448			6.68*	0.009	
rs5288	7.28*	0.007	2.101	0.147	EFT		2.58	0.108	
CYP17A1									0.047
rs6163	3.322	0.190	0.726	0.695			5.424*	0.019	
rs4919685	3.696	0.158	1.465	0.481			4.16*	0.040	
rs619824	0.11	0.946	4.231	0.121			4.236*	0.039	
CYP19A1									0.084
rs10046	2.616	0.270	1.692	0.429			0.136	0.712	

					Additional data			
rs767199	1.009	0.604	0.404	0.817		0.016	0.898	
rs1902585	1.8	0.407	0.964	0.617		4.678*	*0.030*	
rs11636639	0.019	0.990	0.077	0.962		0.85	0.356	
CYP21A2								
rs6467	0.234	0.890	1.529	0.466		0.337	0.562	
SRD5A1								
rs12418164	1.767	0.413	2.57	0.277		1.739	0.187	
SRD5A2								
rs12467911	2.854	0.240	0.554	0.758		0.5671	0.451	
rs12470143	0.002	0.999	1.014	0.602		0.36	0.840	
POR								
rs3898649	1.058	0.589	1.232	0.540		0.4219	0.516	
rs7804806	2.629	0.269	1.675	0.433		1.868	0.172	
rs2286821	3.146	0.207	3.411	0.182		0.3584	0.549	
SHBG								
rs6257	3.227	0.199	3.616	0.164	Eyes	1.556	0.212	
rs6259	1.828	0.401	3.984	0.136	EFT	0.92	0.337	
SCP2								0.095
rs7552139	0.517	0.772	1.356	0.508		0.4819	0.488	
rs7548389	0.069	0.966	0.121	0.941		0.007	0.930	
rs12747412	0.984	0.612	1.193	0.551		4.356*	*0.036*	
rs1288362	0.874	0.646	2.079	0.354		1.141	0.285	
TSPO (PBR)								
rs13056026	0.41	0.815	4.2	0.122		2.901	0.080	
rs3937387	0.36	0.835	3.243	0.198		0.5256	0.469	
rs138922	1.383	0.501	3.127	0.209		0.8165	0.366	
SLC25A12								
rs3821095	3.961	0.138	2.321	0.313		3.551	0.059	
rs6433317	0.467	0.792	5.042	0.080		2.117	0.146	
rs10497374	1.447	0.485	1.066	0.587		0.9971	0.318	
SLC25A13								
rs11773446	3.696	0.158	1.048	0.592		0.814	0.367	
rs10278888	2.291	0.318	0.405	0.817		0.4002	0.527	
rs2301629	0.454	0.797	2.935	0.231		1.17	0.279	

χ^2 statistics and corresponding P-values are reported for all analyses on AQ, EQ, and case–control data (Experiments 1 and 2), and values ≤ 0.05 have been italicized and asterisked. Only significant associations (at two-tailed $P \leq 0.05$) with performance measures (Eyes Test, EFT) are indicated in the column marked "Additional data." For X-linked genes, test statistics are reported separately for males and females, in that order. Corrected P-values after family wise error rate correction using 1,000 permutations are indicated for genes with nominally significant SNPs, and values ≤ 0.05 have been italicized. [Color table can be viewed online at www.interscience.wiley.com]

their correlation structure. The multiple phenotypes for each subject were permuted together so as to preserve the correlation structure among phenotypes. Each SNP was then tested for association to each permuted phenotype and the minimum P-value recorded. The permutation was repeated 1,000 times and the corrected P-value was the estimated proportion of permutations in which the minimum P-value was less than or equal to the minimum P-value seen in the original data. When the family wise error rate (FWER)-corrected P-value is significant, we may infer that at least one SNP in the gene is associated and that there is gene-wise significance. This gene-wise P-value thus reflects the P-value of the most significant SNP after FWER correction.

Results

In Experiment 1, autistic traits (measured on AQ and/or EQ) were nominally associated at $P \leq 0.05$ with SNPs from 19 genes. In Experiment 2, SNPs from 14 genes were nominally associated at $P \leq 0.05$ with AS. The results of the codominant test (2 d.f.) for Experiment 2 were very similar to the ones obtained by the Cochrane-Armitage trend test (1 d.f. χ^2), and are reported in Supplementary Table S2. Across both experiments, six genes showed nominal significance at $P \leq 0.05$. (see Fig. 1 for a summary of all nominally significant genes across the two experiments). A complete list of genotyped SNPs (grouped by gene), with their corresponding test statistics

and nominal and family wise error rate (FWER)-corrected P-values, is reported in Table II.

In Experiment 1, 8 of the 68 genes showed gene-wise significance after 1,000 permutations, across all four phenotypes (AQ, EQ, Eyes Test, EFT). In Experiment 2, five genes showed gene-wise significance after 1,000 permutations. Two genes (*CYP11B1* and *NTRK1*) survived FWER correction in both the experiments (see Tables II and III). In Experiment 1, the probability of at least 8 out of 71 tests (65 autosomal+3 X-linked genes which were analyzed separately for males and females) being nominally significant atp ≤ 0.05, if all null hypotheses are true, is given by the binomial distribution as $P = 0.025$. Thus, while variation in this set of candidate genes could have no impact on the quantitative traits, our results suggest the choice of candidate genes is not random with respect to the quantitative traits. We report all associations that reach the nominal $P \leq 0.05$ (Table II), with the understanding that the family-wise null hypothesis is rejected and the nominally significant genes are the strongest candidates for further replication. Genes that have nominally significant SNPs in both experiments are indicated in Table III, in order to show the direction of association for each SNP. This reveals a largely consistent direction of association for nominally associated SNPs across both experiments, and provides evidence for a partial replication. SNPs in 17 genes showed nominally significant association with cognitive performance measures (Eyes Test and/or EFT), and these are indicated in Table II.


Figure 1. 27 genes showing nominal association with either (1) AS case-control analysis, and/or (2) autistic trait measures (AQ, EQ) in the population sample. The interaction summarizes genes that show a nominal association in both experiments. Gene functional groups are color coded: Pink [medium grey] (sex hormone related), Yellow [dark grey] (neural connectivity related), and Light grey (social–emotional responsivity related). Genes in bold indicate replications of associations reported in earlier studies. * indicates a nominally significant association with EQ. [Color figure can be viewed online at www.interscience.wiley.com]

Table III.   List of the Six Genes that Show Nominal Significance at $P \leq 0.05$ in Both Experiments

Gene		χ^2	P-value (uncorr)				χ^2	P-value (uncorr)	Odds ratio	Cases			Controls		
				Experiment 1						Experiment 2					
NTRK1	EQ			CC	CT	TT				CC	CT	TT	CC	CT	TT
rs6337		1.37	0.505	*0.104*	*0.3425*	*0.555*	7.54	0.010	1.696	*0.09*	*0.32*	*0.60*	*0.16*	*0.40*	*0.45*
				50.03	40.88	44.5									
				TT	GT	GG				TT	TG	GG	TT	TG	GG
rs6339		9.184	0.010	*0.01*	*0.12*	*0.87*	0.2	0.650	1.155	*0.01*	*0.14*	*0.86*	*0.01*	*0.12*	*0.88*
				48	43.9	43.93									
NTRK3	AQ			GG	AG	AA				GG	AG	AA	GG	AG	AA
rs920069		11.984	0.002	*0.5455*	*0.39*	*0.06*	2.03	0.150	0.777	*0.52*	*0.39*	*0.08*	*0.45*	*0.43*	*0.12*
				16.99	16	13.95									
				AA	AG	GG				AA	AG	GG	AA	AG	GG
rs1369430		3.63	0.163	*0.1754*	*0.4892*	*0.3354*	4.66	0.030	0.698	*0.46*	*0.46*	*0.08*	*0.36*	*0.48*	*0.15*
				14.19	16.75	17.18									
ARNT2	AQ			AA	AG	GG				AA	AG	GG	AA	AG	GG
rs4778599		11.127	0.004	*0.1*	*0.45*	*0.44*	2.37	0.120	0.754	*0.11*	*0.32*	*0.57*	*0.11*	*0.44*	*0.44*
				12.3	16.7	16.8									
				TT	TC	CC				TT	TC	CC	TT	TC	CC
rs3901896		3.25	0.197	58	140	115	8.45	0.003	0.600	*0.12*	*0.41*	*0.47*	*0.24*	*0.42*	*0.35*
				14.88	16.87	16.43									
ESR1	AQ			CC	CT	TT				CC	CT	TT	CC	CT	TT
rs11155819		7.178	0.028	*0.11*	*0.42*	*0.47*	3.773	0.052	1.433	*0.15*	*0.41*	*0.44*	*0.05*	*0.45*	*0.50*
				17.4	16.8	16.2									
				AA	AG	GG				AA	AG	GG	AA	AG	GG
rs7774230		1.41	0.494	*0.104*	*0.4128*	*0.4832*	3.978	0.046	1.386	*0.29*	*0.48*	*0.23*	*0.21*	*0.49*	*0.31*
				16.06	16.63	16.34									
ESR2	AQ			AA	AC	CC				AA	AC	CC	AA	AC	CC
rs1271572		17.3	0.0001	0.2	0.4367	0.3608	3.04	0.080	0.745	*0.16*	*0.46*	*0.39*	*0.22*	*0.47*	*0.31*
				15.28	15.15	18.72									
				GG	GC	CC				GG	GC	CC	GG	GC	CC
rs1152582		14.3	0.001	*0.1824*	*0.465*	*0.3526*	4.236	0.039	0.717	*0.15*	*0.47*	*0.38*	*0.21*	*0.51*	*0.28*
				15.18	15.39	18.45									
CYP11B1	EQ			TT	TC	CC				TT	TC	CC	TT	TC	CC
rs4541		1.05	0.593	0.003	0.036	0.96	6.68	0.009	0.091	*0.00*	*0.01*	*0.99*	*0.01*	*0.05*	*0.94*
				29	44	43.69									
				GG	GT	TT				GG	GT	TT	GG	GT	TT
rs5288		7.28	0.007	0	0.1	0.99	2.58	0.108		*0.00*	*0.02*	*0.98*	*0.00*	*0.00*	*1.00*
				0.00	63.30	43.80									

Genotype frequencies for each nominally associated SNP is shown in italics. χ^2 statistics and associated P-values are reported for both experiments, and odds ratios are reported for Experiment 2. For genes with multiple nominally associated SNPs with the same quantitative trait, the SNP with the strongest association is shown. For Experiment 1, mean trait scores for each genotypic group is reported. For Experiment 2, proportion of participants in the AS group ($N = 174$) and the control group ($N = 155$) are indicated next to each genotype.

Haplotype analysis was attempted for all the genes with multiple nominally significant SNPs, using UNPHASED. This did not reveal any significantly associations, either with the case–control data or with the quantitative trait data. This is like to be due to the insufficient coverage of each gene by the multiple SNPs.

Discussion

This is the first hypothesis-driven study to test for genes associated with autistic traits in a population sample, and in a case–control sample for AS. Nominally significant SNPs in 19 genes were found to be associated with one or both of AQ and EQ (measures of autistic traits) in a typical adult sample. SNPs in 14 genes showed a nominally significant difference in allele frequency in the AS case–control analysis. Six of these genes were associated with both autistic traits in Experiment 1 as well as with AS in Experiment 2, suggesting a degree of internal replication. After correcting for multiple SNPs and phenotypes, SNPs in eleven genes remained significant across both experiments. This is more than would be expected from a random selection of candidate genes.

CYP11B1 and *NTRK1* were found to be significant, after FWER correction, in both the experiments, making these the strongest candidates for further replication. Of the 27 nominally associated genes, five of them (*NLGN4X*, *OXTR*, *GABRB3*, *HOXA1*, *EN2*) have been reported in earlier association studies of classic autism. Seventeen genes also showed significant association with performance measures of autistic traits (Eyes Test or EFT), seven of which (*EN2*, *HSD17B4*, *CYP11B1*, *VIPR1*, *NTRK3*, *HSD17B2*, *GABRA6*) overlapped with the genes associated with AQ and/or EQ. Table IV shows a summary of the most significant genes in the two experiments, that survive FWER correction, along with mouse phenotypes and relevant human data, where available. In Table IV and the following section, we discuss these genes in more detail.

Sex Hormones-Related Genes

ASC are associated with strong sex differences, with males and females receiving a diagnosis of classic autism in a ratio of 4:1, and a diagnosis of AS in a ratio of 9:1 [Wing, 1988]. Our study found that SNPs from ten genes related to sex hormone synthesis and metabolism were nominally significant in the case–control and/or the quantitative trait association analysis. Three of these (*CYP11B1*, *CYP17A1*, and *ESR2*) survived FWER correction.

In the *ESR2* gene, the C allele in rs1271572 and rs1152582 were associated with higher AQ in the typical population, and were also found to be more frequent in cases than in controls (Table III and Fig. 2). A similar pattern of results was seen for the nominally significant SNP rs11155819 in the *ESR1* gene. *ESR1* and *ESR2* code for

the two main estrogen receptors. In the fetal brain testosterone is aromatized to estradiol and exerts its effects on neural development through acting on these receptors, and mediating selective cell survival. It promotes the defeminization of the developing male brain in mice [Kudwa, Bodo, Gustafsson, & Rissman, 2005]. Estrogen is thought to mediate social interaction in rodents, and this is supported by the presence of estrogen receptors in areas of the brain involved in emotion and affective behavior, such as the amygdala and the hippocampus. In addition, estradiol, acting through ER-β receptors (homologous to ESR2 in humans), is crucial for dendritic development in cerebellar Purkinje cells in mice [Sakamoto, Mezaki, Shikimi, Ukena, & Tsutsui, 2003]. Given that cerebellar Purkinje cell abnormalities have consistently been reported in autism, this finding represents a convergent genetic lead.

To the best of our knowledge, specific studies looking at estrogen in ASC have not yet been carried out. However, testosterone is converted to estradiol and acts through estrogen receptors in the developing rodent brain [Kudwa et al., 2005], and variations in the estrogen receptors can affect testosterone action.

Longitudinal studies from our laboratory over the last 10 years have found levels of fetal testosterone in typically developing children are negatively correlated with eye contact, vocabulary development [Lutchmaya, Baron-Cohen, Raggatt, & Manning, 2004], empathy [Knickmeyer, Baron-Cohen, Raggatt, & Taylor, 2005; Chapman et al., 2006]. Fetal testosterone levels are also positively correlated with narrow interests [Knickmeyer et al., 2005], systemizing [Auyeung et al., 2006], and autistic traits as measured using the AQ [Auyeung et al., 2009]. The ratio of testosterone to estrogen is also thought to affect the 2nd to 4th digit ratio (2D:4D), which is masculinized in ASC.

CYP17 catalyses the production of dehydroepiandrosterone (DHEA, a precursor of testosterone), as well as androstenedione (a precursor of estradiol). Polymorphisms of this gene have been associated with Polycystic Ovary Syndrome (PCOS) in women [Park et al., 2008]. We have previously reported an increased rate of PCOS and other testosterone-related medical conditions in women with ASC [Ingudomnukul, Baron-Cohen, Wheelwright, & Knickmeyer, 2007]. Hence this too represents a convergent finding. The products of *CYP17A1* are also known to be involved in neocortical organization in the developing rodent brain [Compagnone & Mellon, 1998]. *CYP11B1* is cellularly localized in the mitochondria and converts 11-deoxycortisol to cortisol. Polymorphisms in this gene and the *CYP11A* gene are associated with congenital adrenal hyperplasia (CAH) [Kuribayashi et al., 2005] in which FT is elevated. CAH is associated with higher AQ than in the general population [Knickmeyer et al., 2005]. rs4541 and rs5288 are nonsynonymous coding polymorphisms in *CYP11B1*, which were significant in both

Table IV. Summary of All Significant Genes that Survive FWER Correction, Grouped by Functional Category

GENE_NAME	Gene symbol	Chromosomal position	Observations in human relevant to ASC	Behavioral phenotype in animal models
HOMEOBOX A1	**HOXA1**	7p15.3	Homozygous truncating mutations in HOXA1 interferes with brain development and results in a myriad of phenotypes including mental retardation and autism [Tischfield, 2005].	KO mice show disrupted hindbrain patterning [Rossel et al., 1999].
NEUROTROPHIC TYROSINE KINASE, RECEPTOR, TYPE 1	NTRK1	1q21–q22	Mutations associated with congenital pain insensitivity in humans [Indo, 2001].	KO mice show severe sensory and sympathetic neuropathy, especially for nociceptive neurons [Smeyne et al., 1994; Patel et al., 2000].
ARYL-HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR 2	ARNT2	15q24	Expression of Arnt2 is known to be limited to the neural tissues in mice (No human data available).	Arnt2 KO mice die shortly after birth and exhibit hypocellular supraoptic nuclei (SON) and the paraventricular nuclei (PVN) in the hypothalamus. Secretory neurones expressing arginine vasopressin, oxytocin, corticotrophin-releasing hormone and somatostatin are completely absent in SON and PVN [Hosoya, 2001].
NEUROLIGIN 4, X-LINKED	**NLGN4X**	Xp22.32–p22.31	NLGN mutations associated with autism [Ylisaukko-oja et al., 2004; Jamain et al., 2003].	KO mice show drastically reduced inhibitory neurotransmission in brainstem [Varoqueaux et al., 2006].
WOLFRAM SYNDROME 1 (WOLFRAMIN)	WFS1	4p16	Mutations associated with Wolfram Syndrome, marked by progressive neurodegeneration [Inoue et al., 1998]. Haplotypes associated with affective disorders [Koido et al., 2004].	Mice exposed to cat odour show overexpression in amygdala [Koks et al., 2002].
GAMMA-AMINOBUTYRIC ACID (GABA) A RECEPTOR, BETA 3	**GABRB3**	15q11.2–q12	A chromosomal deletion in this region is associated with Angelman syndrome, marked by hypersocialization [Knoll et al. 1989; DeLorey et al., 2007].	KO mice show spontaneous seizures and abnormal background EEG patterns [DeLorey et al., 2007] and cochlear neuropathy [Maison et al., 2006].
OXYTOCIN, PREPRO- (NEUROPHYSIN I)	OXT	20p13	OT infusion reduces repetitive behaviour in people with autism [Hollander et al., 2003], and increases trust and empathy in control humans [Kosfeld et al., 2005].	KO mice show abnormal social recognition [Ferguson et al., 2001].
MONOAMINE OXIDASE B	MAOB	Xp11.23	Partial deletions of locus is associated with social behavioural deficits in females [Good et al., 2003].	An increased response to stress in Maob-deficient mice [Grimsby et al., 1997].
CYTOCHROME P450, FAMILY 11, SUBFAMILY B, POLYPEPTIDE 1	CYP11B1	8q21	This enzyme has 11-β-hydroxylase activity and mutations in this gene are associated with CAH. [Helmberg et al., 1992; Kuribayashi et al., 2005].	Cyp11b1 mRNA is expressed in the rat amygdala and cerebral cortex and is associated with sex differences [Mellon et al., 1993].
ESTROGEN RECEPTOR 2 (ER BETA)	ESR2	14q23.2	Abundnt expression of Esr2 mRNA in the hippocampal formation (primarily the subiculum), claustrum, and cerebral cortex; expression also in the subthalamic nucleus and thalamus (ventral lateral nucleus) [Osterlund et al., 2000].	Esr2ko male mice show increased female-typical behaviour. Esr2 KO female mice exhibit enhanced anxiety and significantly lower serotonin (5-HT) content in the bed nucleus of the stria terminalis, preoptic area, and hippocampus [Imwalle, 2005].
CYTOCHROME P450, FAMILY 17, SUBFAMILY A, POLYPEPTIDE 1	CYP17A1	10q24.3	Catalyses the formation of the precursors of both testosterone and oestradiol in the adrenal gland. Polymorphisms have been associated with Polycystic Ovary Syndrome in women [Park et al., 2008] which is more frequent in women with ASC (see text).	A gene knockout causes embryonic lethality in mice [Blair & Mellon, 2004]. Haploinsufficiency of this gene is associated with dysregulated steroidigenesis and infertility in male mice [Liu et al., 2005].

Mouse phenotypes and relevant human data are included, where available. Gene functional groups are colour coded in the online version of the table: Pink [medium grey] (Sex hormone related), Yellow [dark grey] (Neural connectivity related) and Light grey (Social–emotional responsivity related). Full references are provided in S3 (Supplementary material). Gene names in bold indicate replication of previously reported associations with classic autism. [Color table can be viewed online at www.interscience.wiley.com]

Figure 2. rs1271572 in the *ESR2* gene is one of several SNPs that show a convergent effect across the two experiments (for a list of these SNPs, see Table III). The left panel displays the AQ scores of each genotype in the typical sample (Experiment 1). Boxes denote the 1st to 3rd quartiles, and the central line denotes the median AQ score. Box width is proportional to the number of individuals in each genotype. The right panel is a bar chart showing the case–control distribution for each genotype in Experiment 2 (grey [blue], ASC participants; black [red], control participants).

the case-control analysis and associated with EQ and the Eyes Task in the general population.

It should be noted though that different SNPs were significant in the two experiments. rs5288 was significant in Experiment 1, but showed no significant differences in allelic frequency between cases and controls in Experiment 2. rs4541 showed a significant difference in allele frequency between cases and controls, but was not associated with a significant difference in mean EQ scores between the different genotypic groups in Experiment 1. This could be due to a variety of factors including limited gene coverage, stochastic variation in LD between the two samples or sampling variations. Additionally in the case–control analysis, a nominally significant association was seen for rs1902585 in *CYP19A1*. This gene codes for aromatase, the enzyme that converts testosterone to estradiol. Together, these results implicate genes involved in the synthesis and metabolism of sex steroids in the etiology of both ASC and autistic traits, possibly pointing to an abnormal balance of testosterone in estrogen signalling. At the time of this article going to press, a study by Hu et al. [2009] has just been published, which reports increased expression of genes related to androgen signalling in autistic children compared to their non-autistic siblings. Together, this provides some of the first genetic evidence in support of the role of

sex-steroids in the etiology of ASC [Baron-Cohen, Knickmeyer, & Belmonte, 2005].

Genes Involved in Neural Development and Connectivity

Abnormal neural connectivity has been proposed to underlie ASC [Belmonte et al., 2004]. Our study found that SNPs from eight genes involved in neural development and connectivity were nominally associated with the case–control and/or the quantitative trait analysis. Four of these (*HOXA1*, *NLGN4X*, *NTRK1*, and *ARNT2*) survived FWER correction.

rs10951154 in *HOXA1* has been previously associated with head size in ASC [Conciatori et al., 2004] as well as with head growth rate [Muscarella et al., 2006]. Our result shows that G-allele carriers are associated with a higher AQ than the AA homozygotes. This is consistent with the finding that the G-allele has been found to be associated with larger head size and greater head growth rate [Muscarella et al., 2006]. rs12836764 in the *NLGN4X* UTR was significantly associated with both EQ and AQ in females. This supports earlier findings implicating this gene in autism [Jamain et al., 2003; Yan et al., 2005]. A large-scale association study of autism found a significant association with neurexins [AGP, 2007] that interact with neuroligins in mediating glutamatergic synaptogenesis. rs1861972 in the *EN-2* gene was associated with EQ in our population sample, although this did not survive a FWER correction. This provides partial support for an earlier report of this SNP being associated with autism [Benayed et al., 2005]. In addition to replicating these earlier findings, we found five hitherto unreported genes in this functional group that were associated with AS or autistic traits. These include three members of the neurotrophin family, particularly *NTRK1*, *NTRK3*, and *NTF3*. SNPs in *NTRK1* showed a significant association in both the experiments, which survived FWER correction at $P < 0.05$. *NTRK1* is situated within a peak (1q21–22) reported in the first ever linkage study of AS [Ylisaukko-oja et al., 2004] and thus provides an independent validation. Nerve growth factor (NGF), signalling through TrkA (the protein product of *NTRK1*), mediates most neurotrophic action of NGF [Sofroniew, Howe, & Mobley, 2001]. A primary role of the TrkA in the developing brain is in determining the fate and growth of neurites, in whether they become axons or dendrites [Da Silva, Hasegawa, Miyagi, Dotti, & Abad-Rodriguez, 2005]. Given the known abnormalities in structural and functional connectivity in the autistic brain, *NTRK1* provides an interesting candidate for future research.

It should be noted that different SNPs were significant in the two experiments, which again maybe due to a range of factors such as limited gene coverage, stochastic variation in LD between the two samples, or sampling variations. NTRK3 and NTF3 is a ligand–receptor pair in the neurotrophin family of molecules that are expressed from

very early in development, and is involved in the formation of the neural tube. Two SNPs in *NTRK3* were found to be nominally associated in both experiments, but neither survived a FWER correction. Two SNPs in the *ARNT2* gene were found to be associated in both the experiments, and survived FWER correction in Experiment 2. rs4778599 in this gene showed a consistent effect across both the experiments, in that the C-allele was associated with a higher AQ score (Experiment 1) and a trend toward a greater proportion of participants with an ASC diagnosis (Experiment 2). This gene is involved both in the development of the neuroendocrine cells in the hypothalamus [Michaud, DeRossi, May, Holdener, & Fan, 2000] as well as in the neural response to hypoxia [Maltepe, Keith, Arsham, Brorson, & Simon, 2000].

These findings point to a key role played by these neurodevelopmental genes in the development of autistic traits.

Genes Involved in Social–Emotional Responsivity

Social–emotional responsivity is one of the core cognitive and behavioral domains marked by impairments in ASC. We found SNPs from nine genes linked to social–emotional responsivity (largely from animal models) to be nominally associated with ASC and/or autistic traits. Four of these (*MAOB*, *GABRB3*, *WFS1*, *OXT*) survived FWER correction.

MAOB was significantly associated in females only, and this is consistent with the earlier studies showing the importance of this locus in social cognition, both in humans and mouse models [Good et al., 2003; Grimsby et al., 1997]. MAOB knockout mice are also known to demonstrate a heightened response to novelty and a lack of habituation [Lee, Chen, Shih, & Hiroi, 2004]. These features resemble those seen in ASC. The rationale for testing GABA-related genes came from the fact that social behavior has been linked to GABA-ergic activity in the CNS [File & Seth, 2003], and that GABA receptors play a crucial role early in cortical development through their effect on neuronal migration as well as on the development of excitatory and inhibitory synapses [Di Cristo, 2007]. In this sense, GABA-related genes could have been placed in both the neurodevelopmental group of candidate genes too. We found *GABRB3* was significantly associated with EQ in the typical sample, thus corroborating a role of this locus (15q11–q13) in autism [Ashley-Koch et al., 2006; Buxbaum et al., 2002]. Gabrb3 knockout mice have been shown to demonstrate low social and exploratory behavior as well as smaller cerebellar vermal volumes, pointing to a potential animal model for autism [DeLorey, Sahbaie, Hashemi, Homanics, & Clark, 2007].

Another significant association in this functional class of genes was the Wolframin (*WFS1*) gene. Wolframin is strongly expressed in the amygdala, especially in response to fear-inducing stimuli. The amygdala is one of the key brain regions where functional and structural abnormalities have been consistently found in ASC [Baron-Cohen et al., 2000]. Two SNPs in *WFS1* showed a strong association with both AQ and EQ. One of these, rs734312, is a nonsynonymous coding SNP and belongs to a haplotype that shows an increased risk for affective disorders [Koido et al., 2004]. This result supports a role for this gene in emotional responsivity.

Three genes from the oxytocin-vasopressin system (*OXTR*, *OXT*, and *AVPR1B*) were found to be nominally associated with ASC and/or with AQ and EQ. These genes have suggestive links with autism [Insel, O'Brien, & Leckman, 1999; Wu et al., 2005] and/or social behavior in animal models. Of these, *OXT* survived a FWER correction in Experiment 2. Oxytocin is of particular interest, given the recent reports of oxytocin levels being low in autism, and treatment effects of both intranasal and intravenous administration of oxytocin [Hollander et al., 2003]. Oxytocin levels are also correlated with empathy and prosocial measures, such as the Eyes Test [Domes, Heinrichs, Michel, Berger, & Herpertz, 2007] and trust in neuroeconomic studies [Kosfeld, Heinrichs, Zak, Fischbacher, & Fehr, 2005]. These provide partial support for the involvement of the oxytocin–vasopressin system in autistic traits. Together, these results support the idea that genes implicated in social and emotional responsivity contribute to individual differences in traits related to ASC.

Functional Overlap Between Gene Groups

A detailed pathway analysis will be reported elsewhere, but we briefly mention some interactions between the three functional categories of genes associated with ASC and/or autistic traits. Sexual dimorphism begins before gonadal sex has been determined [De Vries et al., 2002]. For example, *ARNT2* shows a sexually dimorphic pattern of expression in the brain before gonadal differentiation has occurred [Dewing, Shi, Horvath, & Vilian, 2003]. Chromosomal sex is thus the first step in the development of sexual dimorphism in the brain. A second step involves patterns of sex steroid synthesis and metabolism, from around week 12 in utero. The role of testosterone in affecting neural development by averting programmed cell death, influencing neural connectivity, and altering neurochemical profiles is well established [Baron-Cohen et al., 2005]. Estradiol is known to upregulate TrkA in the developing brain, which suggests a neuroprotective function for it [Sohrabji, Miranda, & Toran-Allenrand, 1994]. The sex steroids also modulate neurotransmitter systems involved in social–emotional responsivity. For example, testosterone and estradiol modulate GABAergic and serotoninergic transmission [Robichaud & Debonnel, 2005] and vasopressin expression [Han & De Vries, 2003]. The neurotrophins and GABA-related genes also interact during cortical development [Lujan, Shigemoto, & Lopez-Bendito, 2005]. This is

to emphasize that although the three functional gene groups were selected independently, there are extensive interactions between them in nature—a detailed treatment of these is beyond the scope of this study.

This is the first candidate gene association study of AS, and of autistic traits in the general population. However, our study also has some limitations. First, our sample sizes were moderate and we deliberately restricted the minor allele frequency of our genotyped SNPs to those >20%. None of our results would survive an experiment-wide Bonferroni correction for the total number of genes tested. However, it should be noted that the unlike a hypothesis-free whole genome association study using ~1 million probes, the multiple comparison problem is several orders of magnitude lower (216 SNPs), so a Bonferroni correction would be too conservative for our analysis [Edwin, 2008; Moran, 2003]. Second, the controls in the case–control analysis were drawn from the general population sample used for the AQ/EQ association analysis, so these two analyses are not completely independent. As an initial exploratory study, our results have generated promising leads and these await independent replication. Finally, we have relied on self-reported ethnicity for all participants, which might be susceptible to subtle confounds due to population stratification.

Despite these limitations, we have succeeded in demonstrating association in the set of candidate genes chosen, significantly higher than would be expected from a random selection of genes. This is important because this study was designed to test multiple strong candidates, rather than being an exploratory whole-genome scan. Our prior belief in each candidate was fairly strong and certainly higher than it would be in a scan. It is therefore reasonable to report genes with gene-wise significance. Because this is based on the number of genes reaching nominal significance, we suggest all such genes are plausible targets for further replication. A caveat is that the genotyping density was variable across genes, owing to the constraints of allele frequency and extent of linkage disequilibrium, so that there is variability in power. Since we tested only a subset of the common variants within each gene, we refrain from speculating on the mechanisms of possible ''risk alleles'' in the development of autistic traits. We are following up these initial associations with fine-mapping of the causal variants, which may reveal genetic mechanisms with more precision.

Additionally, while treating AS as a milder subgroup of autism without comorbid conditions is a novel and useful approach in refining the phenotype, there is a need to conduct replication studies on this set of significant genes in a sample with classic autism. We are currently testing this in our lab.

In this study, we have identified 27 nominally significant candidate genes, some of which are associated with autistic traits in the general population and/or AS. These genes fall into the three functional categories related to sex-steroid synthesis and metabolism, neural development and connectivity, and social–emotional responsivity, providing some support for three theories of autism. Our future studies will test these genes in expression studies, as well as in classic autism to establish which combination of common SNPs (which individually are nonpathological) are common to the etiology of any ASC.

Acknowledgment

References

Abrahams, B., & Geschwind, D. (2008). Advances in autism genetics: on the threshold of a new neurobiology. Nature Review Genetics, 9, 341–355.

AGP. (2007). Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nature Genetics, 39, 319–328.

APA. (1994). DSM-IV diagnostic and statistical manual of mental disorders, 4th Edition. Washington, DC: American Psychiatric Association.

Ashley-Koch, A., Mei, H., Jaworski, J., Ma, D., Ritchie, M., et al. (2006). An analysis paradigm for investigating multi-locus effects in complex disease: examination of three GABA A receptor subunit genes on 15q11–q13 as risk factors for autistic disorder. Annals of Human Genetics, 70, 281–292.

Auyeung, B., Baron-Cohen, S., Chapman, E., Knickmeyer, R., Taylor, K., & Hackett, G. (2006). Foetal testosterone and the child systemizing quotient. European Journal of Endocrinology, 155, 123–130.

Auyeung, B., Baron-Cohen, S., Ashwin, E., Knickmeyer, R., Taylor, K., & Hackett, G. (2009). Fetal testosterone and autistic traits. British Journal of Psychology, 100, 1–22.

Bailey, A., Le Couteur, A., Gottesman, I., Bolton, P., Simmonoff, E., et al. (1995). Autism as a strongly genetic disorder: evidence from a British twin study. Psychological Medicine, 25, 63–77.

Baird, G., Simonoff, E., Pickles, A., Chandler, S., Loucas, T., et al. (2006). Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). The Lancet, 368, 210–215.

Baron-Cohen, S. (1995). Mindblindness: an essay on autism and theory of mind. Boston: MIT Press/Bradford Books.

Baron-Cohen, S., & Hammer, J. (1997). Parents of children with Asperger syndrome: what is the cognitive phenotype? Journal of Cognitive Neuroscience, 9, 548–554.

Baron-Cohen, S., & Wheelwright, S. (2004). The empathy quotient (EQ). An investigation of adults with Asperger syndrome or

high functioning autism, and normal sex differences. Journal of Autism and Developmental Disorders, 34, 163–175.

Baron-Cohen, Joliffe, T., Mortimore, C., & Robertson, M. (1997). Another advanced test of theory of mind: evidence from very high functioning adults with autism or Asperger Syndrome. Journal of Child Psychology and Psychiatry, 38, 813–822.

Baron-Cohen, S., Ring, H., Bullmore, E., Wheelwright, S., Ashwin, C., & Williams, S. (2000). The amygdala theory of autism. Neuroscience and Behavioural Reviews, 24, 355–364.

Baron-Cohen, S., Wheelwright, S., Hill, J., Raste, Y., & Plumb, I. (2001a). The ''reading the mind in the eyes'' test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. Journal of Child Psychiatry and Psychiatry, 42, 241–252.

Baron-Cohen, S., Wheelwright, S., Skinner, R., Martin, J., & Clubley, E. (2001b). The Autism Spectrum Quotient (AQ): evidence from Asperger syndrome/high functioning autism, males and females, scientists and mathematicians. Journal of Autism and Developmental Disorders, 31, 5–17.

Baron-Cohen, S., Lutchmaya, S., & Knickmeyer, R. (2004). Prenatal testosterone in mind: amniotic fluid studies. Cambridge, MA: MIT/Bradford.

Baron-Cohen, S., Knickmeyer, R.C., & Belmonte, M.K. (2005). Sex differences in the brain: implications for explaining autism. Science, 310, 819–823.

Belmonte, M.K., Allen, G., Beckel-Mitchener, A., Boulanger, L., Carper, R., & Webb, S. (2004). Autism and abnormal development of brain connectivity. Journal of Neuroscience, 24, 9228–9231.

Benayed, R., Gharani, N., Rossman, I., Mancuso, V., Lazar, G., et al. (2005). Support for the homeobox transcription factor gene engrailed 2 as an autism spectrum disorder susceptibility locus. American Journal of Human Genetics, 77, 851–868.

Billington, J., Baron-Cohen, S., & Wheelwright, S. (2007). Cognitive style predicts entry into physical sciences and humanities: questionnaire and performance tests of empathy and systemizing. Learning and Individual Differences, 17, 260–268.

Bishop, D., Maybery, M., Maley, A., Wong, D., Hill, W., & Hallmayer, J. (2004). Using self-report to identify the broad phenotype in parents of children with autistic spectrum disorders: a study using the Autism Spectrum Quotient. Journal of Child Psychology and Psychiatry, 45, 1431–1436.

Buxbaum, J.D., Silverman, J., Smith, C.J., Greenberg, D.A., Kilfarski, M., et al. (2002). Association between a GABRB3 polymorphism and autism. Molecular Psychiatry, 7, 311–316.

Chakrabarti, B., Kent, L., Suckling, J., Bullmore, E.T., & Baron-Cohen, S. (2006). Variations in human cannabinoid receptor (CNR1) gene modulate striatal response to happy faces. European Journal of Neuroscience, 23, 1944–1948.

Champagne, F., Weaver, I., Diorio, J., Dymov, S., Szyf, M., & Meaney, M.J. (2006). Maternal care associated with methylation of the estrogen receptor-alpha1b promoter and estrogen receptor-alpha expression in the medial preoptic area of female offspring. Endocrinology, 147, 2909–2915.

Chapman, E., Baron-Cohen, S., Auyeung, B., Knickmeyer, R., Hackett, G., & Taylor, K. (2006). Foetal testosterone and empathy: evidence from the empathy quotient (EQ) and the ''reading the mind in the eyes test''. Social Neuroscience, 1, 135–148.

Collins, F.S., Guyer, M.S., & Chakravarti, A. (1997). Variations on a theme: cataloging human DNA sequence variation. Science, 278, 1580–1581.

Compagnone, N.A., & Mellon, S.H. (1998). Dehydroepiandros-terone: a potential signalling molecule for neocortical organisation during development. Proceedings of National Academy of Science USA, 95, 4678–4683.

Conciatori, M., Stodgell, C., Hyman, S., O'Bara, M., Militerni, R., et al. (2004). Association between the HOXA1 A218G polymorphism and increased head circumference in patients with autism. Biological Psychiatry, 55, 413–419.

Constantino, J., & Todd, R. (2005). Intergenerational transmission of subthreshold autistic traits in the general population. Biological Psychiatry, 57, 655–660.

Dawson, G., Carver, L.J., Meltzoff, A.N., Panagiotides, H., McPartland, J., & Webb, S.J. (2002). Neural correlates of face and object recognition in young children with autism spectrum disorder, developmental delay and typical development. Child Development, 73, 700–717.

Da Silva, J.S., Hasegawa, T., Miyagi, T., Dotti, C.G., & Abad-Rodriguez, J. (2005). Asymmetric membrane ganglioside sialidase activity specifies axonal fate. Nature Neuroscience, 8, 544–546.

De Vries, G., Rissman, E., Simerley, R.B., Yang, L., Scordalakes, E.M., et al. (2002). A model system for study of sex chromosome effects on sexually dimorphic neural and behavioural traits. The Journal of Neuroscience, 22, 9005–9014.

DeLorey, T.M., Sahbaie, P., Hashemi, E., Homanics, G.E., & Clark, J.D. (2007). Gabrb3 gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: a potential model of autism spectrum disorder. Behavioural Brain Research, 187, 207–220.

Dewing, P., Shi, T., Horvath, S., & Vilian, E. (2003). Sexually dimorphic gene expression in mouse brain precedes gonadal differentiation. Molecular Brain Research, 118, 82–90.

Di Cristo, G. (2007). Development of cortical GABAergic circuits and its implications for neurodevelopmental disorders. Clinical Genetics, 72, 1–8.

Dorris, L., Espie, C.A.E., Knott, F., & Salt, J. (2004). Mindreading difficulties in the siblings of people with Asperger's syndrome: evidence for a genetic influence in the abnormal development of a specific cognitive domain. Journal of Child Psychology and Psychiatry, 45, 412–418.

Domes, G., Heinrichs, M., Michel, A., Berger, C., & Herpertz, S.C. (2007). Oxytocin improves mindreading in humans. Biological Psychiatry, 61, 731–733.

Dudbridge, F. (2008). Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Human Heredity, 66, 89–98.

Edwin, J.C.G.v.d.O. (2008). Controlling false discoveries in genetic studies. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 147B, 637–644.

File, S.E., & Seth, P. (2003). A review of 25 years of the social interaction test. European Journal of Pharmacology, 463, 35–53.

Gillberg, C. (1991). Clinical and neurobiological aspects of Asperger syndrome in six family studies. In: Frith, U., editor.

Autism and Asperger syndrome. Cambridge: Cambridge University Press.

Good, C.D., Lawrence, K., Simon-Thomas, N., Price, C.J., Ashburner, J., et al. (2003). Dosage-sensitive X-linked locus influences the development of amygdala and obitofrontal cortex, and fear recognition in humans. Brain, 126, 1–16.

Grimsby, J., Toth, M., Chen, K., Kumazawa, T., Klaidman, L., et al. (1997). Increased stress response and bold beta-phenylethylamine in MAOB-deficient mice. Nature Genetics, 17, 206–210.

Han, T., & De Vries, G. (2003). Organizational effects of testosterone, estradiol, and dihydrotestosterone on vasopressin mRNA expression in the bed nucleus of the stria terminalis. Journal of Neurobiology, 54, 502–510.

Hoekstra, R., Bartels, M., Verweij, C., & Boomsma, D. (2007). Heritability of autistic traits in the general population. Archives of Pediatric and Adolescent Medicine, 161, 372–377.

Hollander, E., Novotny, S., Hanratty, M., Yaffe, R., DeCaria, C., et al. (2003). Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology, 28, 193–198.

Hu, V.W., Nguyen, A., Kim, K.S., Steinberg, M.E., Sarachana, T., Scully, M.A., et al. (2009). Gene expression profiling of lymphoblasts from autistic and nonaffected sib pairs: altered pathways in neuronal development and steroid biosynthesis. PLoS ONE, 4, e5775.

ICD-10. 1994. International classification of diseases. Geneva, Switzerland: World Health Organisation.

ICD-10. 1994. International classification of diseases. Geneva, Switzerland: World Health Organisation.

Ingudomnukul, E., Baron-Cohen, S., Wheelwright, S., & Knickmeyer, R. (2007). Elevated rates of testosterone-related disorders in women with autism spectrum conditions. Hormones and Behavior, 51, 597–604.

Insel, T., O'Brien, D., & Leckman, J. (1999). Oxytocin, vasopressin, and autism: is there a connection? Biological Psychiatry, 45, 145–157.

Jamain, S., Quach, H., Betancur, C., et al. (2003). Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nature, 34, 27–29.

Jolliffe, T., & Baron-Cohen, S. (1997). Are people with autism or Asperger's syndrome faster than normal on the embedded figures task? Journal of Child Psychology and Psychiatry, 38, 527–534.

Knickmeyer, R., Baron-Cohen, S., Raggatt, P., & Taylor, K. (2005). Foetal testosterone, social cognition, and restricted interests in children. Journal of Child Psychology and Psychiatry, 46, 198–210.

Koido, K., Kõks, S., Nikopensius, T., Maron, E., Altmäe, S., et al. (2004). Polymorphisms in wolframin (WFS1) gene are possibly related to increased risk for mood disorders. The International Journal of Neuropsychopharmacology, 8, 235–244.

Kosfeld, M., Heinrichs, M., Zak, P.J., Fischbacher, U., & Fehr, E. (2005). Oxytocin increases trust in humans. Nature, 435, 673–676.

Kudwa, A. E., Bodo, C., Gustafsson, J.A., & Rissman, E.F. (2005). A previously uncharacterized role for estrogen receptor {beta}: defeminization of male brain and behavior. Proceedings of the National Academy of Sciences USA, 102, 4608.

Kuribayashi, I., Nomoto, S., Massa, G., Oostdijk, W., Wit, J., et al. (2005). Steroid 11-beta-hydroxylase deficiency caused by compound heterozygosity for a novel mutation, p G314R, in one CYP11B1 allele, and a chimeric CYP11B2/CYP11B1 in the other allele. Hormone Research, 63, 284–293.

LaBuda, M., Gottesman, I., & Pauls, D. (1993). Usefulness of twin studies for exploring the etiology of childhood and adolescent psychiatric disorders. American Journal of Medical Genetics, 48, 47–59.

Lawrence, E.J., Shaw, P., Baker, D., Baron-Cohen, S., & David, A.S. (2004). Measuring empathy—reliability and validity of the empathy quotient. Psychological Medicine, 34, 911–919.

Lee, M., Chen, K., Shih, J., & Hiroi, N. (2004). MAO-B knockout mice exhibit deficient habituation of locomotor activity but normal nicotine intake. Genes, Brain and Behavior, 3, 216–227.

Losh, M., & Piven, J. (2007). Social-cognition and the broad autism phenotype: identifying genetically meaningful phenotypes. Journal of Child Psychology and Psychiatry, 48, 105–112.

Lujan, R., Shigemoto, R., & Lopez-Bendito, G. (2005). Glutamate and GABA signalling in the developing brain. Neuroscience, 130, 567–580.

Lutchmaya, S., Baron-Cohen, S., Raggatt, P., & Manning, J.T. (2004). Maternal 2nd to 4th digit ratios and foetal testosterone. Early Human Development, 77, 23–28.

Maltepe, E., Keith, B., Arsham, A., Brorson, J., & Simon, M. (2000). The role of ARNT2 in tumor angiogenesis and the neural response to hypoxia. Biochemical and Biophysical Research Communications, 273, 231–238.

Michaud, J., DeRossi, C., May, N., Holdener, B., & Fan, C. (2000). ARNT2 acts as the dimerization partner of SIM1 for the development of the hypothalamus. Mechanisms of Development, 90, 253–261.

Moran, M.D. (2003). Arguments for rejecting the sequential Bonferroni in ecological studies. Oikos, 100, 403–405.

Muscarella, L., Guarnieri, V., Sacco, R., Militerni, R., Bravaccio, C., et al. (2007). HOXA1 gene variants influence head growth rates in humans. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 144B, 388–390.

Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A.R., et al. (2007). PLINK: a toolset for whole-genome association and population-based linkage analysis. American Journal of Human Genetics, 81, 559–575.

Robichaud, M., & Debonnel, G. (2005). Oestrogen and testosterone modulate the firing activity of dorsal raphe nucleus serotonergic neurones in both male and female rats. Journal of Neuroendocrinology, 17, 179–185.

Sakamoto, H., Mezaki, Y., Shikimi, H., Ukena, K., & Tsutsui, K. (2003). Dendritic growth and spine formation in response to estrogen in the developing Purkinje cell. Endocrinology, 144, 4466–4477.

Sofroniew, M., Howe, C., & Mobley, W. (2001). Nerve growth factor signaling, neuroprotection, and neural repair. Annual Review of Neuroscience, 24, 1217–1281.

Sohrabji, F., Miranda, R., & Toran-Allenrand, C.D. (1994). Estrogen differentially regulates estrogen and nerve growth factor receptor mRNAs in adult sensory neuron. Journal of Neuroscience, 14, 459–471.

Sung, Y., Dawson, G., Munson, J., Estes, A., Schellenberg, G., & Wijsman, E. (2005). Genetic investigation of quantitative traits related to autism: use of multivariate polygenic models

with ascertainment adjustment. The American Journal of Human Genetics, 76, 68–81.

Wakabayashi, A., Baron-Cohen, S., & Wheelwright, S. (2006). Are autistic traits an independent personality dimension? A study of the Autism Spectrum Quotient (AQ) and the NEO-PI-R. Personality and Individual Differences, 41, 873–883.

Wing, L. 1988. The autistic continuum. In: Wing, L., editor. Aspects of autism: biological research. London: Gaskell/Royal College of Psychiatrists.

Woodbury-Smith, M., Robinson, J., Wheelwright, S., & Baron-Cohen, S. (2005). Screening adults for Asperger syndrome using the AQ: a preliminary study of its diagnostic validity in clinical practice. Journal of Autism and Developmental Disorders, 35, 331–335.

Wu, S., Jia, M., Ruan, Y., Liu, J., Guo, Y., et al. (2005). Positive association of the oxytocin receptor gene (OXTR) with autism in the Chinese Han population. Biological Psychiatry, 58, 74–77.

Yan, J., Oliveira, G., Coutinho, A., Yang, C., Feng, J., et al. (2005). Analysis of the neuroligin 3 and 4 genes in autism and other neuropsychiatric patients. Molecular Psychiatry, 10, 329–332.

Ylisaukko-oja, T., Nieminen-von Wendt, T., Kempas, E., Sarenius, S., Varilo, T., et al. (2004). Genome-wide scan for loci of Asperger syndrome. Mol Psychiatry, 9, 161–168.

Zahn-Waxler, C., Robinson, J.L., & Emde, R.N. (1992). The development of empathy in twins. Developmental Psychology, 28, 1038–1047.

Supplementary Material S1: Biological rationale for inclusion of each gene in the current association study for ASC and related normative traits.

Supplementary Table S2: Codominant test statistics for Experiment 2. 2 d.f. chi square chi-square statistics and corresponding P-values are reported for all SNPs. For X-linked genes, test statistics are reported separately for males and females, in that order.

Supplementary Material S3: Full references for Table 4

Biological rationale for inclusion of each gene in the current association study for ASC and related normative traits.

1. Sex hormone-related genes

Classic autism as well as autistic traits are associated with strong sex differences, a fact that led to the extreme male brain (EMB) theory of autism[1, 2]. The drive to empathize is stronger in females while males show a stronger drive to systemise[3, 4]. We therefore tested genes related to testosterone and oestrogen synthesis, metabolism and transport. Plasma testosterone (T) levels have been reported to be elevated in children with autism[5]. Foetal testosterone (FT) levels correlate negatively with eye-contact at 12 months old [6], vocabulary size at 24 months old [7], social development at 4 years old [8], and score on the EQ and the Eyes test at 8 years old [9]. FT levels correlate positively with narrow interests at 4 years old [8], Systemizing Quotient (SQ) and AQ at 8 years old [10]. T acts through the intracellular androgen receptor, encoded by *AR1*. T is aromatised to oestradiol (through aromatase, encoded by *CYP19A1*), binding to the oestrogen receptors (ER-α or ER-β, coded by *ESR1* and *ESR2* respectively), influencing transcription.Oestradiol, acting through ER-β receptors (homologous to ESR2 in humans) is crucial for dendritic development in cerebellar Purkinje cells in mice [93]. We therefore tested *AR1* and *ESR1* and *ESR2*, which are interesting because of their role in sexually dimorphic brain regions such as the amygdala, which itself plays a key role in emotion perception and is abnormal in ASC[11, 12]. Oestrogen interacts with serotonergic systems involved in regulating affect[13], and affective disorders[14]. Steroid hormones share a common synthesis pathway with cholesterol as the

ultimate precursor. Smith-Lemli-Opitz Syndrome (SLOS), a cholesterol deficiency syndrome in which *(DHCR7)* is implicated, is marked by a near-universal presence of ASC[15, 16].

Cytochrome p450 subtypes and hydroxysteroid dehydrogenases (HSDs) acting on cholesterol, produce progesterone, oestrogen, cortisol, aldosterone and T. A mutation in *CYP21A2* is associated with congenital adrenal hyperplasia (CAH), a condition marked by an excessive production of androgens and an elevated number of autistic traits as measured with the AQ[8]. While major mutations in the steroid/sex hormone synthesis pathway are unlikely to produce ASC or autistic traits, SNPs in genes from the *CYP* superfamily could encode for subtle shifts in steroid balance. Consequently, we genotyped 24 SNPs from 10 genes of the *CYP* superfamily (see Table 2). The hydroxysteroids (HSD)s are a class of enzymes involved in tissue-specific regulation of sex steroids. 11β-HSD catalyses both the 11-β-dehydrogenation and the reverse 11-oxoreduction reactions in the glucocorticoid pathway. Additional genes involved in steroid hormone metabolism (*STS, SULT2A1*) were also included. Genes involved in a subset of the carrier proteins involved in intracellular transport of sex steroids, as well as their precursors and metabolites, included *SHBG, SCP2, TSPO, SLC25A12, SLC25A13*. TSPO and SCP2 play an important role in the transport of cholesterol within the cell. Testosterone may be carried in the plasma in a bound or unbound form. Only the unbound form is metabolically active; 66% of testosterone is bound to SHBG. The equilibrium between bound and unbound testosterone provided by SHBG is therefore important in regulating testosterone activity (but not total levels). Mixed evidence suggests a possible association of *SLC25A12* with classic autism[17-19].

2. Genes involved in neural development and connectivity

Since ASC is neurodevelopmental, we also tested genes involved in neural growth, synaptic proliferation and pruning[20]. A growing number of studies show functional[21] and structural[22] underconnectivity in the autistic brain[23], where abnormal growth patterns have been documented[24]. We hypothesized that minor variations in genes governing neural connectivity could contribute to autistic traits. These fell into 3 categories:

Neurotrophins and their receptors

These are involved in neuronal survival, differentiation and growth. NGFB signals primarily through NTRK1 and NGFR, BDNF through NTRK2 and NTF3 through NTRK3 as well as NTRK1. *VGF* is upregulated by NGF, and is expressed in neuroendocrine cells. VEGF acts on endothelial cells by promoting cell growth and migration, especially during angiogenesis and vasculogenesis, both processes that can be triggered by hypoxia. In endothelial cell cultures, effects of VEGF are modulated directly by PTEN[25], the gene that has recently been linked to proposed mouse model of autism[26]. Interestingly, perinatal hypoxia has been identified as one of the potential risk factors for infantile autism[27]. ARNT2 is another vital component in this pathway, in mediating the neural response to hypoxia[28]. RAPGEF4 is a negative regulator of Rap1A, which is involved in cellular growth and differentiations in neurons. Mutations in the *RAPGEF4* gene has been linked to autism in a previous family based association study[29].

Proteins involved in formation and maintenance of neuronal connections

Neuroligins are transmembrane proteins expressed post-synaptically that are involved in synapse formation and maintenance in CNS neurons through their interaction with β-neurexins[30-32]. Several rare mutations in the *NLGN4* gene have been linked to ASC[33-

35]. Neuronal Cell Adhesion Molecule (NRCAM) is involved in neuron-neuron adhesion and promotes directional signaling during axonal cone growth. Agrin is best known for its role in cholinergic synaptogenesis especially at neuromuscular junctions [36], as well as in synaptic differentiation in CNS neurons[37].

Proteins with a more systemic role in development

Engrailed-1 (EN-1) and Engrailed-2 (EN-2) are among the best studied homeobox transcription factors involved in early neuronal migration[38-40] which play a crucial role in cerebellar development in mice[41]. In humans, the *EN-2* gene is located in 7q.36, a region linked to ASC[42-45], and where developmental abnormalities in cerebellar structure have been reported[46, 47]. HOXA1 is a member of the evolutionarily conserved superfamily of homeodomain containing transcription factors, and is involved in hindbrain patterning[48]. There is mixed evidence linking abnormalities in this gene with ASC[49-51].

3.Genes underlying social-emotional responsivity

Since both ASC and autistic traits have a core feature of reduced sociality and empathy, we tested genes implicated in social-emotional responsivity, falling into 3 categories:

Oxytocin, Opioid and Cannabinoid systems

Endogenous reward systems have been postulated to underlie social attachment in humans and other mammals[52-54]. Opioids and cannabinoids are the main molecules in these systems, which work in tandem with the mesolimbic dopaminergic system. The mu opioid receptor is believed to be the most important of all the opioid receptors that, like morphine,

binds enkephalins and beta-endorphin. Blocking this receptor results in reduced maternal behaviour in rodents and sheep as well as in large primates[55]. It is expressed in the ventral striatum in humans[56], a region known for its role in reward processing. The cannabinoid receptor 1 (CNR1) is expressed is in the brain, and mediates social behaviour in rat pups. In a neuroimaging study[57], *CNR1* variations predicted striatal 'reward' response to happy but not disgust faces. *TRPV1* encodes for the vanilloid receptor, which binds to a variety of endogenous cannabinoids as well as to capsaicin. Dopamine and serotonin are key neurotransmitters underlying reward and motivation, and MAOB is involved in their synaptic breakdown. This locus has been linked to social cognition[58].

The oxytocin system has been implicated in social recognition and social attachments[59] as well as maternal behaviour, infant separation distress and sexual relationships. OT and vasopressin are closely related neuropeptides. Oxytocin knockout mice demonstrate social recognition deficits that are restored by central OT administration into the amygdala[60], which is involved in emotion processing. Receptors for oxytocin, which also bind vasopressin, are located in the limbic system, forebrain and autonomic centres in the brainstem. There are 2 central brain receptors for vasopressin (V1aR and V1bR). Vasopressin receptor 1a is important in formation of pair bonds, parental behaviour as well as the infant's behaviour to social separation[61]. The social attachment differences between the monogamous and the promiscuous voles are linked to differences in the neural distribution of OT and AVP receptors[52, 62]. V1a receptors transfected to the ventral pallidal region of male prairie voles result in increased affiliative behaviour, as well as quicker and stronger attachment formation to partners of the opposite sex[63]. Male knockout mice for the vasopressin 1A receptor demonstrate impairments in social recognition but no other

memory deficits[62] and the V1bR knockout mouse also shows disruption of social memory[64]. The expression of these receptors in the ventral striatal region suggests a strong link between social behaviour and reward. *OXTR* is located at 3p26.2 and *AVPR1A* and *AVPR1B* are located at 12q14 and 1q32 respectively. Several genome scans have reported linkage in the region 3p23-3p25.2.[44, 65] and previous association studies have implicated a possible role for *AVPR1A*[66, 67]and the oxytocin receptor gene in autism susceptibility[68]. Additionally, findings from a whole genome linkage study of AS[69] overlap with those previously reported in autism linkage scans. Oxytocin effects on social processing in the amygdala make this a strong candidate given the amygdala abnormalities (in structure and function) in ASC[11, 70, 71].

GABA – related genes

GABA is the main inhibitory neurotransmitter in the human brain, where it primarily binds to GABA-A receptors. GABA receptors are interesting candidate genes for ASC and autistic traits because of the role of GABA receptors in early cortical development[72], primarily through mediating tangential migration of neurons; because previous association studies of ASC have implicated GABA receptors; and because GABA-A receptors are strongly expressed in the human prefrontal cortex and the cerebellum[73-75]. Neuroimaging and lesion studies have suggested that both these regions play crucial roles in theory of mind in people with and without ASC[76, 77].

GABRB3 is expressed in the amygdala, prefrontal cortex and the globus pallidus among other brain regions. Variation in this locus has been associated with ASC in several linkage studies[78, 79]. An expression study on post-mortem brains showed reduced levels of

GABRB3 transcript in autism[80]. GABRG3 is located on the same chromosomal region (15q11-q13) and is part of the same network of genes associated with ASCs[81]. GABRA6 is downregulated in rats who showed lower anxiety response to cat odour[82], suggesting a possible role for the gene in fear sensitivity. In humans, it is expressed in cerebellar granule cells in the brain and plays an important role in their differentiation[83]. A polymorphism in the GABRA6 gene has been shown to be associated with self-report measures of perceived parenting, a quantitative measures of early attachment[84] in humans. Another study has reported an association of this gene with 'cooperativeness'[85].

ABAT catabolises GABA from synapses into succinic semialdehyde. Two whole-genome screening studies of autism have indicated this chromosomal region (16p) as a putative susceptibility locus[86, 87]. A recent association study[88] reported a moderate haplotypic difference in the *ABAT* gene between ASC cases and controls.

Wolframin

Expression levels of the wolframin gene are elevated in the rat amygdala after being exposed to cat odour, and hence has been hypothesised to underlie the fear response in rats[89, 90]. The amygdala is known for its important role in emotion processing[91] and its atypical structure and function in ASC[11, 70, 71]. This gene is also associated with affective disorder[92].

References for Online-Only Material S1

1.   Baron-Cohen, S., *The extreme male brain theory of autism.* Trends in Cognitive Sciences, 2002. 6: p. 248-254.
2.   Baron-Cohen, S., R.C. Knickmeyer, and M.K. Belmonte, *Sex Differences in the Brain: Implications for Explaining Autism.* Science, 2005. 310(5749): p. 819-823.

3.   Lawson, J., S. Baron-Cohen, and S. Wheelwright, *Empathising and systemising in adults with and without Asperger Syndrome.* Journal of Autism and Developmental Disorders, 2004. 34: p. 301-310.

4.   Baron-Cohen, S., *The systemizing quotient: an investigation of adults with Asperger syndrome or high-functioning autism, and normal sex differences.* Philosophical Transactions: Biological Sciences, 2003. 358(1430): p. 361-374.

5.   Tordjman, A., et al., *Plasma androgens in autism.* Journal of Autism and Developmental Disorders, 1995. 25(295-305).

6.   Lutchmaya, S., S. Baron-Cohen, and P. Raggett, *Foetal testosterone and eye contact in 12 month old infants.* Infant Behavior and Development, 2002. 25: p. 327-335.

7.   Lutchmaya, S., S. Baron-Cohen, and P. Raggatt, *Foetal testosterone and vocabulary size in 18- and 24-month-old infants.* Infant Behavior and Development, 2002. 24(4): p. 418-424.

8.   Knickmeyer, R., et al., *Foetal testosterone, social cognition, and restricted interests in children.* Journal of Child Psychology and Psychiatry, 2005. 46(2): p. 198-210.

9.   Chapman, E., et al., *Foetal testosterone and empathy: evidence from the Empathy Quotient (EQ) and the 'Reading the mind in the Eyes Test'.* Social Neuroscience, 2006. 1: p. 135-148.

10.   Auyeung, B., et al., *Foetal testosterone and the child systemizing quotient.* European Journal of Endocrinology, 2006. 155(1): p. 123-30.

11.   Baron-Cohen, S., et al., *The amygdala theory of autism.* Neuroscience and Behavioural Reviews, 2000. 24: p. 355-364.

12.   Shaw, P., et al., *The role of the amygdala in social sensitivity.* Annals NY Academy of Sciences, 2004. 985: p. 508-510.

13.   Amin, Z., T. Canli, and C. Epperson, *Effect of estrogen-serotonin interactions on mood and cognition.* Behavioural and Cognitive Neuroscience Reviews, 2005. 4(1): p. 43-58.

14.   Payne, J., *The role of estrogen in mood disorders in women.* International Review of Psychiatry, 2003. 15(3): p. 280-290.

15.   Sikora, D., et al., *The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome.* Am J Med Genet A, 2006. 140(14): p. 1511-8.

16.   Tierney, E., et al., *Behavior phenotype in the RSH/Smith-Lemli-Opitz syndrome.* American Journal of Medical Genetics, 2001. 98(2): p. 191-200.

17.   Ramoz, N., et al., *Linkage and association of the mitochondrial aspartate/glutamate carrier SLC25A12 gene with autism.* Am J Psychiatry, 2004. 161(4): p. 662-9.

18.   Rabionet, R., et al., *Lack of Association Between Autism and SLC25A12*
      Am J Psychiatry, 2006. 163(5): p. 929-931.

19.   Segurado, R., et al., *Confirmation of Association Between Autism and the Mitochondrial Aspartate/Glutamate Carrier SLC25A12 Gene on Chromosome 2q31.* Am J Psychiatry, 2005. 162(11): p. 2182-2184.

20.   Belmonte, M., et al., *Autism as a disorder of neural information processing : directions for research and targets for therapy.* Molecular Psychiatry, 2004. 9: p. 646-663.

21.   Just, M., et al., *Cortical activation and synchronization during sentence comprehension in high-functioning autism: evidence of underconnectivity.* Brain, 2004. 127: p. 1811-1821.

22.   Barnea-Goraly, N., et al., *White matter structure in autism: preliminary evidence from diffusion tensor imaging.* Biological Psychiatry, 2004. 55(3): p. 323-326.

23.   Belmonte, M., K,, et al., *Autism and abnormal development of brain connectivity.* J Neurosci, 2004. 24(42): p. 9228-9231.

24. Courchesne, E., et al., *Autism at the beginning: Microstructural and growth abnormalities underlying the cognitive and behavioral phenotype of autism.* Development and Psychopathology, 2005. 17(03): p. 577-597.

25. Huang, J. and C. Kontos, *PTEN Modulates Vascular Endothelial Growth Factor-Mediated Signaling and Angiogenic Effects.* Journal of Biological Chemistry, 2002. 277(13): p. 10760-10766.

26. Kwon, C., et al., *Pten Regulates Neuronal Arborization and Social Interaction in Mice.* Neuron, 2006. 50(3): p. 377-388.

27. Hultman, C., P. Sparen, and S. Cnattingius, *Perinatal risk factors for infantile autism.* Epidemiology, 2002. 13(4): p. 417-423.

28. Maltepe, E., et al., *The role of ARNT2 in tumor angiogenesis and the neural response to hypoxia.* Biochem Biophys Res Commun, 2000. 273(1): p. 231-8.

29. Bacchelli, E., et al., *Screening of nine candidate genes for autism on chromosome 2q reveals rare nonsynonymous variants in the cAMP-GEFII gene.* Molecular Psychiatry, 2003. 8: p. 916-924.

30. Scheiffele, P., *Cell-cell signalling during synapse formation in the CNS.* Annual Review of Neuroscience, 2003. 26: p. 485-508.

31. Chubykin, A., et al., *Dissection of synapse induction by neuroligins: effect of a neuroligin mutation associated with autism.* Journal of Biological Chemistry, 2005. 280: p. 22365-22374.

32. Cline, H., *Synaptogenesis: A balancing act between excitation and inhibition.* Current Biology, 2005. 15(6): p. R204-R206.

33. Laumonnier, F., et al., *X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family.* Am J Hum Genet, 2004. 74(3): p. 552-7.

34. Jamain, S., et al., *Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism.* Nature, 2003. 34.

35. Yan, J., et al., *Analysis of the neuroligin 3 and 4 genes in autism and other neuropsychiatric patients.* Molecular Psychiatry, 2005. 10: p. 329-332.

36. Gautam, M., et al., *Defective neuromuscular synaptogenesis in agrin-deficient mutant mice.* Cell, 1996. 85(4): p. 525-35.

37. Bose, C.M., et al., *Agrin Controls Synaptic Differentiation in Hippocampal Neurons.* J. Neurosci., 2000. 20(24): p. 9086-9095.

38. Gibert, J.-M., *The evolution of engrailed genes after duplication and speciation events.* Dev Genes Evol, 2002. 212: p. 307-318.

39. Friedman, G. and D. O'Leary, *Retroviral misexpression of engrailed genes in the chick optic tectum perturbs the topographic targeting of retinal axons.* J Neurosci, 1996. 16(17): p. 5498-5509.

40. Sauressig, H., J. Burrill, and M. Goulding, *Engrailed-1 and Netrin-1 regulate axon pathfinding by association interneurons that project to motor neurons.* Development, 1999. 126: p. 4201-4212.

41. Millen, K., et al., *Abnormal embryonic cerebellar development and patterning of postnatal foliation in two mouse Engrailed-2 mutants.* Development, 1994. 120(3): p. 695-706.

42. Liu, J., et al., *A genomewide screen for autism susceptability loci.* American Journal of Human Genetics, 2001. 69: p. 327-340.

43. Alarcon, M., et al., *Autism Genetic Research Exchange Consortium: Evidence for a language quantitative trait locus on chromosome 7q in multiplex autism families.* American Journal of Human Genetics, 2002. 70: p. 60-71.

44.   Auranen, M., et al., *A genomewide screen for autism-spectrum disorders : evidence for a major susceptibility locus on chromosome 3q25-27.* American Journal of Human Genetics, 2002. 71(4): p. 777-90.

45.   Gharani, N., et al., *Association of the homeobox transcription factor, ENGRAILED 2, with autism spectrum disorder.* Mol Psychiatry, 2004. 9(5): p. 540.

46.   Courchesne, E., et al., *Abnormality of cerebellar vermian lobules VI and VII in patients with infantile autism: Identification of hypoplastic and hyperplastic subgroups with MR imaging.* American Journal of Radiology, 1994. 162: p. 123-130.

47.   Courchesne, E., *Abnormal early brain development in autism.* Molecular Psychiatry, 2002. 7: p. 21-23.

48.   del Toro, E., et al., *Generation of a Novel Functional Neuronal Circuit in Hoxa1 Mutant Mice.* Journal of Neuroscience, 2001. 21(15): p. 5637.

49.   Ingram, J., et al., *Discovery of allelic variants of HOXA 1 and HOXB 1: Genetic susceptibility to autism spectrum disorders.* Teratology, 2000. 62(6): p. 393-405.

50.   Conciatori, M., et al., *Association between the HOXA1 A218G polymorphism and increased head circumference in patients with autism.* Biological Psychiatry, 2004. 55(4): p. 413-419.

51.   Li, J., et al., *Lack of Association Between HoxA1 and HoxB1 Gene Variants and Autism in 110 Multiplex Families.* American Journal of Medical Genetics (Neuropsychiatric Genetics), 2002. 114: p. 24-30.

52.   Keverne, E., B,, *Understanding well-being in the evolutionary context of brain development.* Philosophical Transactions of the Royal Society, Series B, 2004. 359: p. 1349-1358.

53.   Panksepp, J., E. Nelson, and M. Bekkedal, *Brain systems for the mediation of social separation-distress and social-reward.* Annals NY Academy of Sciences, 1997. 807: p. 78-100.

54.   Bouvard, M., et al., *Low dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study.* Psychiatry Research, 1995. 58: p. 191-201.

55.   Martel, F., et al., *Opioid receptor blockade reduces maternal affect and social grooming in Rhesus monkeys.* Psychoneuroendocrinology, 1993. 18(4): p. 307-321.

56.   Voorn, P., et al., *Densitometrical analysis of opioid receptor ligand binding in the human striatum -I.Distribution of mu-opioid receptor defines shell and core of the ventral striatum.* Neuroscience, 1996. 75(3): p. 775-792.

57.   Chakrabarti, B., et al., *Variations in human cannabinoid receptor (CNR1) gene modulate striatal response to happy faces.* Eur J Neurosci, 2006. 23(7): p. 1944-1948.

58.   Good, C.D., et al., *Dosage-sensitive X-linked locus influences the development of amygdala and obitofrontal cortex, and fear recognition in humans.* Brain, 2003. 126: p. 1-16.

59.   Insel, T., D. O'Brien, and J. Leckman, *Oxytocin, vasopressin, and autism: is there a connection?* Biol Psychiatry, 1999. 45(2): p. 145-57.

60.   Ferguson, J., et al., *Oxytocin in the Medial Amygdala is Essential for Social Recognition in the Mouse.* Journal of Neuroscience, 2001. 21(20): p. 8278-8285.

61.   Insel, T., *A neurobiological basis of social attachment.* The American Journal of Psychiatry, 1997. 154: p. 726-735.

62.   Bielsky, I., et al., *Profound Impairment in Social Recognition and Reduction in Anxiety-Like Behavior in Vasopressin V 1 a Receptor Knockout Mice.* Neuropsychopharmacology, 2004. 29(3): p. 483-493.

63.   Pitkow, L., et al., *Facilitation of Affiliation and Pair-Bond Formation by Vasopressin Receptor Gene Transfer into the Ventral Forebrain of a Monogamous Vole.* Journal of Neuroscience, 2001. 21(18): p. 7392-7396.

64. Wersinger, S., et al., *Vasopressin V1b receptor knockout reduces aggressive behavior in male mice.* Mol Psychiatry, 2002. 7(9): p. 975-84.

65. Shao, Y., et al., *Fine mapping of autistic disorder to chromsome 15q11-q13 by use of phenotypic subtypes.* American Journal of Human Genetics, 2003. 72: p. 539-548.

66. Kim, S., et al., *Transmission disequilibrium testing of arginine vasopressin receptor 1A (AVPR1A) polymorphisms in autism.* Molecular Psychiatry, 2002. 7: p. 503-507.

67. Wassink, T., et al., *Examination of AVPR1a as an autism susceptibility gene.* Molecular Psychiatry, 2004. 9: p. 968-972.

68. Wu, S., et al., *Positive association of the oxytocin receptor gene (OXTR) with autism in the Chinese Han population.* Biol Psychiatry, 2005. 58(1): p. 74-7.

69. Ylisaukko-oja, T., et al., *Genome-wide scan for loci of Asperger syndrome.* Mol Psychiatry, 2004. 9(2): p. 161-8.

70. McAlonan, G., et al., *Mapping the brain in autism: A voxel based MRI study of volumetric differences and intercorrelations in autism.* Brain, 2005. 128(2): p. 268-276.

71. Skuse, D.H., D. Morris, and K. Lawrence, *The amygdala and development of the social brain.* Annals NY Academy of Sciences, 2003. 1008: p. 91-101.

72. Lujan, R., R. Shigemoto, and G. Lopez-Bendito, *Glutamate and GABA signalling in the developing brain.* Neuroscience, 2005. 130: p. 567-580.

73. Merali, Z., et al., *Dysregulation in the Suicide Brain: mRNA Expression of Corticotropin-Releasing Hormone Receptors and GABA A Receptor Subunits in Frontal Cortical Brain Region.* Journal of Neuroscience, 2004. 24(6): p. 1478-1485.

74. Akbarian, S., et al., *GABA A receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and controls.* Cereb Cortex, 1995. 5(6): p. 550-60.

75. Ohnuma, T., et al., *Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: focus on GABA content, GABA (A) receptor alpha-1 subunit messenger RNA and human GABA transporter-1 (HGAT-1) messenger RNA expression.* Neuroscience, 1999. 93(2): p. 441-8.

76. Frith, U. and C. Frith, *Development and neurophysiology of mentalizing.* Philosophical Transactions of the Royal Society, 2003. 358: p. 459-473.

77. Saxe, R., S. Carey, and N. Kanwisher, *Understanding other minds: linking developmental psychology and functional neuroimaging.* Annual Review of Psychology, 2004. 55: p. 87-124.

78. Buxbaum, J., D,, et al., *Assocation between a GABRB3 polymorphism and autism.* Molecular Psychiatry, 2002. 7: p. 311-316.

79. McCauley, J., et al., *A linkage disequilibrium map of the 1-Mb 15 q 12 GABAA receptor subunit cluster and association to autism.* American Journal of Medical Genetics, 2004. 131(1): p. 51-59.

80. Samaco, R., A. Hogart, and J. LaSalle, *Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3.* Human Molecular Genetics, 2005. 14(4): p. 483-492.

81. Ashley-Koch, A., et al., *An Analysis Paradigm for Investigating Multi-locus Effects in Complex Disease: Examination of Three GABA A Receptor Subunit Genes on 15q11-q13 as Risk Factors for Autistic Disorder.* Annals of Human Genetics, 2006. 70: p. 281-292.

82. Wang, H., et al., *cDNA microarray analysis of gene expression in anxious PVG and SD rats after cat-freezing test.* Experimental Brain Research, 2003. 149: p. 413-421.

83. Wang, W., et al., *A Role for Nuclear Factor I in the Intrinsic Control of Cerebellar Granule Neuron Gene Expression.* J. Biol. Chem., 2004. 279(51): p. 53491-53497.

84. Lucht, M., et al., *Negative perceived paternal parenting is associated with dopamine D? 2 ? receptor exon 8 and GABA (A) alpha 6 receptor variants: An explorative study.* American Journal of Medical Genetics Part B (Neuropsychiatric Genetics), 2006. 141: p. 167-172.

85. Comings, D., et al., *A multivariate analysis of 59 candidate genes in personality traits: the temperament and character inventory.* Clinical Genetics, 2000. 58(5): p. 375-385.

86. IMGSAC, *A genomewide screen for autism : strong evidence for linkage to chromosomes 2q, 7q and 16p.* American Journal of Human Genetics, 2001. 69: p. 570-581.

87. Phillipe, A., et al., *Paris Autism Research International Sibpair Study : Genome-wide scan for autism susceptibility genes.* Human Molecular Genetics, 1999. 8: p. 805-812.

88. Barnby, G., et al., *Candidate-Gene Screening and Association Analysis at the Autism-Susceptibility Locus on Chromosome 16p: Evidence of Association at GRIN2A and ABAT.* Am. J. Hum. Genet, 2005. 76: p. 950-966.

89. Koks, S., et al., *A screen for genes induced in the amygdaloid area during cat odor exposure.* Genes Brain and Behavior, 2004. 3(2): p. 80-89.

90. Koks, S., et al., *Cat odour exposure increases the expression of wolframin gene in the amygdaloid area of rat.* Neurosci Lett, 2002. 322(2): p. 116-20.

91. Calder, A.J., A.D. Lawrence, and A.W. Young, *Neuropsychology of fear and loathing.* Nature Reviews Neuroscience, 2001. 2: p. 352-363.

92. Koido, K., et al., *Polymorphisms in wolframin (WFS1) gene are possibly related to increased risk for mood disorders.* The International Journal of Neuropsychopharmacology, 2004. 8(02): p. 235-244.

93. Sakamoto H, Mezaki Y, Shikimi H, Ukena K, Tsutsui K. 2003. Dendritic growth and spine formation in response to estrogen in the developing Purkinje cell. Endocrinology 144:4466-4477

Supplementary Table S2

EXPERIMENT 2		
Gene variations	C-A Trend Test χ2 Statistic	C-A Trend Test p-value
AGRN		
rs2275813	0.071	0.790
rs8014	1.77	0.180
NRCAM		
rs445372	0.31	0.580
rs1269621	1.45	0.230
rs1269655	1.096	0.290
NTRK1		
rs6334	2.67	0.100
rs6337	7.54*	*0.010*
rs1007211	1.01	0.320
rs6339	0.2	0.650
NTRK2		
rs7027979	0.38	0.540
rs11140776	0.47	0.490
rs10780691	0.002	0.960
rs1490404	0.24	0.620
rs1778934	0.65	0.420
rs2489162	0.03	0.860
rs1619120	0.06	0.810
rs993315	0.77	0.370
rs1624327	0.004	0.950
rs1443444	0.02	0.890
NTRK3		
rs1948066	0.44	0.510
rs7170215	0.41	0.840
rs920069	2.03	0.150
rs1824554	0.15	0.690
rs7170976	0.09	0.750

rs922231	3.12	0.080
rs8030107	2.1	0.150
rs2279409	0.004	0.940
rs11073762	0.011	0.910
rs3784410	0.59	0.440
rs7176429	0.44	0.510
rs1369430	4.66*	*0.030*
rs3784441	1.36	0.240
rs1369423	1.9	0.170
NLGN1		
rs993298	0.6	0.440
NLGN4X		
rs5916338	0.73/0.80	0.39/0.37
rs12836764	0.00006/0.48	0.99/0.49
NGFB		
rs6330	0.01	0.920
rs910330	0.53	0.470
NGFR		
rs575791	3.62	0.057
EN2		
rs2361689	0.07	0.790
rs1861972	0.033	0.850
rs3735653	0.12	0.730
HOXA1		
rs10951154	0.25	0.620
NTF3		
rs6332	0.13	0.720
rs7958038	1.69	0.190
rs7132127	6.5*	*0.010*
rs4930767	1.35	0.250
NTF5		

rs1611775	0.29	0.590
VGF		
rs2074686	1.34	0.250
rs10953325	0.05	0.820
rs1859528	0.85	0.350
VEGF		
rs833068	2.41	0.120
rs3025020	0.25	0.620
RAPGEF4 (cAMP-GEFII)		
rs6754857	0.49	0.485
rs17746510	0.21	0.650
rs2676501	1.38	0.240
TAC1		
rs1229434	3.8	0.052
rs2072100	1.39	0.237
IGF1		
rs11111272	0.049	0.820
rs972936	1.51	0.227
rs2946834	4.31*	*0.037*
rs10735380	0.228	0.630
IGF2		
rs2239681	0.029	0.864
rs11042751	1.054	0.305
rs734351	0.081	0.776
BDNF		
rs6265	0.989	0.320
ARNT2		
rs4778599	2.369	0.120
rs4778795	3.076	0.079

rs11856273	0.003	0.953
rs3901896	8.45*	*0.003*
rs7403073	0.53	0.460
OXT		
rs2740204	1.93	0.160
rs2770378	6.76*	*0.009*
OXTR		
rs237880	1.81	0.180
rs237885	1.069	0.301
rs237898	0.023	0.870
rs2228485	0.37	0.540
rs237902	0.69	0.400
AVPR 1A		
rs1042615	2.177	0.140
AVPR1B		
rs28405931	1.237	0.260
OPRM1		
rs648893	1.315	0.250
rs495491	0.017	0.890
rs1381376	2.304	0.130
rs1799971	0.1459	0.702
CNR1		
rs6454674	0.0004	0.980
rs806380	2.01	0.150
rs806377	0.87	0.350
rs1049353	0.48	0.490
TRPV1		
rs224534	0.31	0.570
rs222747	0.16	0.700
rs8065080	0.0004	0.980
rs224547	0.023	0.880

Gene/SNP		
GABRB3		
rs2873027	2.243	0.134
rs11161335	0.002	0.950
GABRG3		
rs28431127	0.331	0.570
rs4887536	0.49	0.480
GABRA6		
rs13172914	0.11	0.730
rs13183266	0.39	0.530
rs10037092	0.56	0.460
ABAT		
rs2302607	0.2	0.655
rs1731017	0.066	0.790
rs1641010	0.793	0.373
rs2270287	0.046	0.828
rs1641003	3.384	0.068
MAOB		
rs2283729	0.00823/0.72	0.9277/0.397
rs1799836	0.5759/0.20	0.4479/0.65
VIPR		
rs417387	1.47	0.224
rs437876	0.25	0.620
rs342511	1.67	0.196
WFS1		
rs734312	0.006	0.930
rs4234730	0.119	0.730
rs1046322	0.69	0.400
CGRPR		
rs35034167	1.66	0.190

rs1983372	1.84	0.174
CGA		
rs981086	0.2818	0.595
rs9444470	0.337	0.561
rs9342103	2.413	0.120
ESR1		
rs4583998	1.696	0.192
rs1884051	0.542	0.461
rs827421	0.88	0.348
rs2228480	0.2014	0.653
rs11155819	3.773*	0.052
rs7774230	3.978*	*0.046*
rs712221	2.75	0.090
rs6905370	0.21	0.640
rs1801132	1.83	0.176
rs2077647	0.204	0.650
ESR2		
rs1271572	3.04	0.080
rs1256030	1.676	0.195
rs1152579	0.829	0.362
rs1152582	3.332	0.067
rs915057	4.236*	*0.039*
rs1256049	3.079	0.079
AR1		
rs1204039	0.09/2.221	0.759/0.1362
rs5918760	0.013/1.68	0.906/0.942
rs6152	0.01/1.31	0.928/0.352
LHB		
rs753307	1.593	0.206
LHCGR		
rs4555391	4.51*	*0.030*
rs7584253	0.4249	0.515
rs6545061	0.382	0.536

rs2293275	0.033	0.850
GNRHR		
rs2062302	1.15	0.284
rs974483	0.252	0.615
FSHB		
rs532667	2.119	0.146
SULT2A1		
rs2547241	0.1072	0.743
rs182420	0.027	0.868
DHCR7		
rs4944957	0.8783	0.349
rs12419334	0.7621	0.383
rs736894	0.889	0.345
STS		
rs2024159	0.51/1.234	0.82/0.2667
rs7058445	0.06/0.7508	0.806/0.3862
HSD11B1		
rs4844880	2.203	0.138
rs2884090	5.895*	*0.015*
rs11576775	0.6053	0.437
HSD17B2		
rs2873459	0.12	0.729
rs4398102	1.858	0.172
rs4445895	0.285	0.593
rs4497679	0.094	0.758
rs4889456	1.219	0.262
rs6564964	0.7722	0.379
rs8044837	1.61	0.194
HSD17B3		
rs1807197	0.009	0.924
rs1927883	0.006	0.934

rs2026001	1.531	0.215
rs2476920	0.419	0.517
rs2476923	0.4567	0.499
rs371119	0.524	0.469
rs913580	0.076	0.782
HSD17B4		
rs25640	0.063	0.801
rs257973	0.201	0.653
rs32651	0.2877	0.592
rs3850201	0.6343	0.426
rs426899	0.733	0.392
rs7737181	0.1114	0.739
CYP1A1		
rs1456432	0.081	0.776
rs2606345	0.199	0.655
rs4646421	2.45	0.117
CYP1B1		
rs162556	2.236	0.134
rs163086	2.4	0.121
CYP3A		
rs2242480	0.027	0.869
CYP7A1		
rs11786580	0.657	0.417
rs10957056	0.236	0.627
rs1023649	1.44	0.230
CYP11A		
rs2279357	1.22	0.270
CYP11B1		
rs4534	5.68*	*0.017*
rs4541	6.68*	*0.009*
rs5288	2.58	0.108

CYP17A1		
rs6163	5.424*	*0.019*
rs4919685	4.16*	*0.040*
rs619824	4.236*	*0.039*
CYP19A1		
rs10046	0.136	0.712
rs767199	0.016	0.898
rs1902585	4.678*	*0.030*
rs11636639	0.85	0.356
CYP21A2		
rs6467	0.337	0.562
SRD5A1		
rs12418164	1.739	0.187
SRD5A2		
rs12467911	0.5671	0.451
rs12470143	0.36	0.840
POR		
rs3898649	0.4219	0.516
rs7804806	1.868	0.172
rs2286821	0.3584	0.549
SHBG		
rs6257	1.556	0.212
rs6259	0.92	0.337
SCP2		
rs7552139	0.4819	0.488
rs7548389	0.007	0.930
rs12747412	4.356*	*0.036*
rs1288362	1.141	0.285
TSPO (PBR)		
rs13056026	2.901	0.080

rs3937387	0.5256	0.469
rs138922	0.8165	0.366
SLC25A12		
rs3821095	3.551	0.059
rs6433317	2.117	0.146
rs10497374	0.9971	0.318
SLC25A13		
rs11773446	0.814	0.367
rs10278888	0.4002	0.527
rs2301629	1.17	0.279

Online-only material S3

(Full references for Table 4)

Blair SR, Mellon SH. 2004. Deletion of the mouse P450c17 gene causes early embryonic lethality.*Mol. Cell Bio.* 24:5383-90

Blasi F, Bacchelli E, Pesaresi G, Carone S, Bailey A. 2006. Absence of coding mutations in the X-linked genes neuroligin 3 and neuroligin 4 in individuals with autism from the IMGSAC collection. *American Journal of Medical Genetics Part B (Neuropsychiatric Genetics)* 141: 220-1

DeLorey T, Olsen R. 1999. GABA and epileptogenesis: comparing gabrb3 gene-deficient mice with Angelman syndrome in man. *Epilepsy Res* 36: 123-32

DeLorey T, Sahbaie P, Hashemi E, Homanics G, Clark J. 2008. Gabrb3 gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: A potential model of autism spectrum disorder. *Behavioural Brain Research* 187: 207-20

Ferguson J, Aldag J, Insel T, Young L. 2001. Oxytocin in the Medial Amygdala is Essential for Social Recognition in the Mouse. *Journal of Neuroscience* 21: 8278-85

Good CD, Lawrence K, Simon-Thomas N, Price CJ, Ashburner J, et al. 2003. Dosage-sensitive X-linked locus influences the development of amygdala and obitofrontal cortex, and fear recognition in humans. *Brain* 126: 1-16

Grimsby J, Toth M, Chen K, Kumazawa T, Klaidman L, et al. 1997. Increased stress response and bold beta- phenylethylamine in MAOB- deficient mice. *Nature Genetics* 17: 206-10

Helmberg A, Ausserer B, Kofler R. 1992. Frame shift by insertion of 2 basepairs in codon 394 of CYP11B1 causes congenital adrenal hyperplasia due to steroid 11 beta-hydroxylase deficiency. *J Clin Endocrinol Metab* 75: 1278-81

Hollander E, Novotny S, Hanratty M, Yaffe R, DeCaria C, et al. 2003. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. *Neuropsychopharmacology* 28: 193-8

Hosoya T, Oda Y, Takahashi S, Morita M, Kawauchi S, et al. 2001. Defective development of secretory neurones in the hypothalamus of Arnt2-knockout mice. *Genes Cells* 6: 361-74

Imwalle D, Gustafsson J, Rissman E. 2005. Lack of functional estrogen receptor beta influences anxiety behavior and serotonin content in female mice. *Physiol Behav* 84: 157-63

Inoue H, Tanizawa Y, Wasson J, Behn P, Kalidas K, et al. 1998. A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). *Nature Genetics* 20: 143-8

Jamain S, Quach H, Betancur C, al e. 2003. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. *Nature* 34

Knoll J, Nicholls R, Magenis R, Graham Jr J, Lalande M, Latt S. 1989. Angelman and Prader-Willi syndromes share a common chromosome 15 deletion but differ in parental origin of the deletion. *Am J Med Genet* 32: 285-90

Koido K, Kõks S, Nikopensius T, Maron E, Altmäe S, et al. 2004. Polymorphisms in wolframin (WFS1) gene are possibly related to increased risk for mood disorders. *The*

International Journal of Neuropsychopharmacology 8: 235-44

Koks S, Planken A, Luuk H, Vasar E. 2002. Cat odour exposure increases the expression of wolframin gene in the amygdaloid area of rat. *Neurosci Lett* 322: 116-20

Kosfeld M, Heinrichs M, Zak P, Fischbacher U, Fehr E. 2005. Oxytocin increases trust in humans. *Nature* 435: 673-6

Kuribayashi I, Nomoto S, Massa G, Oostdijk W, Wit J, et al. 2005. Steroid 11-Beta-Hydroxylase Deficiency Caused by Compound Heterozygosity for a Novel Mutation, p G314R, in One CYP11B1 Allele, and a Chimeric CYP11B2/CYP11B1 in the Other Allele. *Hormone Research* 63: 284-93

Liu Y, Yao ZX, Bendavid C, Borgmeyer C, Han Z, et al. 2005. Haploinsufficiency of cytochrome P450 17alpha-hydroxylase/17,20 lyase (CYP17) causes infertility in male mice. *Mol. Endocrinol.* 19:2380-2389

Mellon S, Deschepper C. 1993. Neurosteroid biosynthesis: genes for adrenal steroidogenic enzymes are expressed in the brain. *Brain Res* 629: 283-92

Park JM, Lee EJ, Ramakrishna S, Cha DH, Baek KH. 2008. Association study for single nucleotide polymorphisms in the CYP17A1 gene and polycystic ovary syndrome. *International Journal of Molecular Medicine* 22 :249-54

Patel TD, Jackman A, Rice FL, Kucera J, Snider WD. 2000. Development of Sensory Neurons in the Absence of NGF/TrkA Signaling In Vivo. *Neuron* 25: 345-57

Smeyne R, Klein R, Schnapp A, Long L, Bryant S, et al. 1994. Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. *Nature* 368: 246-9

Tischfield M, Bosley T, Salih M, Alorainy I, Sener E, et al. 2005. Homozygous HOXA1 mutations disrupt human brainstem, inner ear, cardiovascular and cognitive development. *Nature Genetics* 37: 1035-7

Varoqueaux F, Aramuni G, Rawson RL, Mohrmann R, Missler M, et al. 2006. Neuroligins Determine Synapse Maturation and Function. *Neuron* 51: 741-54

Westlund K, Denney R, Rose R, Abell C. 1988. Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. *Neuroscience* 25: 439-56

Ylisaukko-oja T, Rehnstrom K, Auranen M, Vanhala R, Alen R, et al. 2005. Analysis of four neuroligin genes as candidates for autism. *European Journal of Human Genetics* 13: 1285-92